WO2003040096A2 - N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives - Google Patents

N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives Download PDF

Info

Publication number
WO2003040096A2
WO2003040096A2 PCT/US2002/036072 US0236072W WO03040096A2 WO 2003040096 A2 WO2003040096 A2 WO 2003040096A2 US 0236072 W US0236072 W US 0236072W WO 03040096 A2 WO03040096 A2 WO 03040096A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
phenyl
optionally substituted
hydroxy
alkoxy
Prior art date
Application number
PCT/US2002/036072
Other languages
English (en)
French (fr)
Other versions
WO2003040096A3 (en
Inventor
Varghese John
Michel Maillard
Barbara Jagodzinska
James P. Beck
Andrea Gailunas
Larry Fang
Jennifer Sealy
Ruth Tenbrink
John Freskos
John Mickelson
Lakshman Samala
Roy Hom
Original Assignee
Elan Pharmaceuticals, Inc.
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP02793909A priority Critical patent/EP1453789A2/en
Application filed by Elan Pharmaceuticals, Inc., Pharmacia & Upjohn Company filed Critical Elan Pharmaceuticals, Inc.
Priority to EA200400648A priority patent/EA200400648A1/ru
Priority to MXPA04004428A priority patent/MXPA04004428A/es
Priority to AU2002359376A priority patent/AU2002359376B2/en
Priority to APAP/P/2004/003049A priority patent/AP2004003049A0/en
Priority to JP2003542142A priority patent/JP2005520791A/ja
Priority to BR0214035-7A priority patent/BR0214035A/pt
Priority to CA002466284A priority patent/CA2466284A1/en
Priority to NZ533107A priority patent/NZ533107A/en
Priority to IL16188102A priority patent/IL161881A0/xx
Priority to ARP020104299A priority patent/AR039555A1/es
Priority to YUP-505/04A priority patent/RS50504A/sr
Publication of WO2003040096A2 publication Critical patent/WO2003040096A2/en
Publication of WO2003040096A3 publication Critical patent/WO2003040096A3/en
Priority to IS7255A priority patent/IS7255A/is
Priority to IL161881A priority patent/IL161881A/en
Priority to TNP2004000082A priority patent/TNSN04082A1/en
Priority to NO20042359A priority patent/NO20042359L/no
Priority to HR20040518A priority patent/HRP20040518A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/40—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/50—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/38—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the invention is directed to compounds useful in treatment of Alzheimer's disease and similar diseases.
  • AD Alzheimer's disease
  • cognitive loss occurs gradually, but typically lead to severe impairment and eventual death in the range of four to twelve years.
  • Alzheimer's disease is characterized by two major pathologic observations in the brain: neurofibrillary tangles and beta amyloid (or neuritic) plaques, comprised predominantly of an aggregate of a peptide fragment know as A beta.
  • Individuals with AD exhibit characteristic beta-amyloid deposits in the brain (beta amyloid plaques) and in cerebral blood vessels (beta* amyloid angiopathy) as well as neurofibrillary tangles.
  • Neurofibrillary tangles occur not only in Alzheimer's disease but also in other dementia-inducing disorders. On autopsy, large numbers of these lesions are generally found in areas of the human brain important for memory and cognition.
  • Amyloidogenic plaques and vascular amyloid angiopathy also characterize the brains of ' individuals with Triso y 21 (Down's Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA- D) , and other neurogenerative disorders.
  • Beta-amyloid is a defining feature of AD, now believed to be a causative precursor or factor in the development of the disease. Deposition of A beta in areas of the brain responsible for cognitive activities is a major factor in the development of AD.
  • Beta-amyloid plaques are predominantly composed of amyloid beta peptide (A beta, also sometimes designated betaA4) .
  • a beta peptide is derived by proteolysis of the amyloid precursor protein (APP) and is comprised of 39-42 amino acids.
  • APP amyloid precursor protein
  • secretases are involved in the processing of APP.
  • Cleavage of APP at the N-terminus of the A beta peptide by beta-secretase and at the C-terminus by one or more gamma- secretases constitutes the beta-amyloidogenic pathway, i.e. the pathway by which A beta is formed.
  • Cleavage of APP by alpha- secretase produces alpha-sAPP, a secreted form of APP that does not result in beta-amyloid plaque formation. This alternate pathway precludes the formation of A beta peptide.
  • An aspartyl protease has been identified as the enzyme responsible for processing of APP at the beta-secretase cleavage site.
  • the beta-secretase enzyme has been disclosed using varied nomenclature, including BACE, Asp, and Memapsin.
  • a beta-amyloid peptide plays a seminal role in the pathogenesis of AD and can precede cognitive symptoms by years or decades. Release of A beta from neuronal cells grown in culture and the presence of A beta in cerebrospinal fluid (CSF) of both normal individuals and AD patients has been demonstrated.
  • CSF cerebrospinal fluid
  • beta peptide accumulates as a result of APP processing by beta secretase, thus inhibition of this enzyme's activity is desirable for the treatement of AD.
  • In vivo processing of APP at the beta-secretase cleavage site is thought to be a rate-limiting step in A beta production, and is thus a therapeutic target for the treatment of AD.
  • BACEl knockout mice fail to produce A beta, and a normal phenotype.
  • the progeny show reduced amounts of A beta in brain extracts as compared with control animals (Luo et. al . , 2001 Nature Neuroscience 4:231-232). This evidence further supports the proposal that inhibition of beta-secretase activity and reduction of A beta in the brain provides a therapeutic method for the treatment of AD and other beta amyloid disorders.
  • Beta-secretase that inhibit beta-secretase-mediated cleavage of APP, that are effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques, are needed for the treatment and prevention of disease characterized by amyloid beta deposits or plaques, such as AD.
  • the invention provides compounds of formula X:
  • Ri is -(CH 2 ) ⁇ -2-S(0)o-2-(C ⁇ -C 6 alkyl), or
  • -OC ( 0) -mono- or dialkylamino, or C 2 -C 6 alkenyl or C 2 -C ⁇ alkynyl, each of which is optionally substituted with 1, 2, or 3 groups independently selected from halogen, -OH, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 3 alkoxy, amino, and mono- or dialkylamino, or aryl, heteroaryl, heterocyclyl, -C ⁇ -C 6 alkyl-aryl, -Ci-C ⁇ alkyl-heteroaryl, or -C ⁇ -C 6 alkyl-heterocyclyl , where the ring portions of each are optionally substituted with 1, 2, 3, or 4 groups independently selected from halogen, -OH, -SH, -C ⁇ N, -NR ⁇ 05 R' ⁇ os, -C0 2 R, -N(R)C0R', or -N(R)S0 2 R',
  • Ci-C ⁇ alkoxy optionally substituted with 1, 2, or 3 groups which are independently selected from halogen, or C 3 -C 7 cycloalkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, OH, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 3 alkoxy, amino, -C ⁇ -C 6 alkyl and mono- or dialkylamino, or
  • Ci-Cio alkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, -OH, -SH, -C ⁇ N, -CF 3 , -Ci-C 3 alkoxy, amino, mono- or dialkylamino and -C ⁇ -C 3 alkyl, or
  • R and R' independently are hydrogen, C 1 -C 10 alkyl, C1-C 1 0 alkylaryl or C 1 -C 1 0 alkylheteroaryl;
  • R is hydrogen, C ⁇ -C 6 alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of C ⁇ -C 3 alkyl, halogen hydroxy, -SH, cyano, -CF 3 , C ⁇ -C 3 alkoxy, amino, mono (Ci-Cg) alkylamino, or di (Ci- C 6 ) alkylamino ;
  • R 3 is selected from the group consisting of hydrogen, C ⁇ -C 6 alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of C ⁇ -
  • R2 1 5, -(CH 2 ) 0 -4-N(H or R 215 )-CO-N(R 2 i5)2, - (CH 2 ) 0-4- -CS- N(R 215 ) 2 , -(CH 2 )o-4-N(-H or R 215 ) -CO-R220, - (CH 2 ) o-4-NR 22 oR 2 25,
  • C 1 -C 10 alkyl optionally substituted with 1, 2, or 3 R205 groups , or C2-C 1 0 alkenyl or C 2 -C ⁇ 0 alkynyl, each of which is optionally substituted with 1 or 2 R 205 groups, wherein the aryl and heteroaryl groups at each occurrence are optionally substituted with 1, 2, or 3 groups that are independently R 2 os/ R210/ or Ci-C ⁇ alkyl substituted with 1, 2, or 3 groups that are independently R 2 os or R210 and wherein the heterocyclyl group at each occurrence is optionally substituted with 1, 2, or 3 groups that are independently R210; R 205 at each occurrence is independently selected from C ⁇ -C 3 alkyl, halogen, -OH, -O-phenyl, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 6 alkoxy, NH 2 , NH(C ⁇ -C 6 alkyl) or N- (C ⁇ -C 6 alkyl) (C
  • R 215 at each occurrence is independently selected from C ⁇ -C 6 alkyl, - (CH 2 ) o- 2 - (aryl) , C 2 -C 5 alkenyl, C 2 -C 6 alkynyl, C 3 _C 7 cycloalkyl, and - (CH 2 ) 0-2- (heteroaryl) , -(CH 2 )o-2-
  • R 220 and R 2 5 at each occurrence are independently selected from -H, -C 3 -C 7 cycloalkyl, - (C ⁇ -C 2 alkyl) - (C3-C7 cycloalkyl), - (C ⁇ -C 6 alkyl) -0-(C ⁇ -C 3 alkyl), -C 2 -C 6 alkenyl, -C 2 -C 6 alkynyl, -Ci-C ⁇ alkyl chain with one double bond and one triple bond, -aryl, -heteroaryl, and -heterocyclyl, or -C 1 -C 10 alkyl optionally substituted with -OH, -NH
  • R245 and R 250 are taken together with the carbon to which they are attached to form a carbocycle of 3, 4, 5, 6, or 7 carbon atoms, where one carbon atom is optionally replaced by a heteroatom selected from -0-, -S-, -S0 2 -, and -NR 220 -; R 255 and R 260 at each occurrence are independently selected from -H, -(CH 2 ) ⁇ _2-S(0)o-2-(C ⁇ -C 6 alkyl), - (C1
  • R26 5 at each occurrence is independently -0-, -S- or -N(C ⁇ -C 6 alkyl ) - ;
  • R1 1 5 groups; W is -(CH 2 ) 0 -4-, -0-, -S(O) 0 -2-, -N(R ⁇ 35 )-, -CR(OH)- or -C(O)-; R102 and R102 ' independently are hydrogen, or
  • C 1 -C 1 0 alkyl optionally substituted with 1, 2, or 3 groups that are independently halogen, aryl or -Rno; R105 and R'105 independently re -H, -R 110 , -R 120/ C 3 -C 7 cycloalkyl, -(C ⁇ -C 2 alkyl) -(C3-C7 cycloalkyl), - (C ⁇ -C 6 alkyl) -0- (C1-C3 alkyl) , C 2 -C 6 alkenyl, C-C 6 alkynyl, or C ⁇ -C 6 alkyl chain with one double bond and one triple bond, or Ci-C ⁇ alkyl optionally substituted with -OH or -NH 2 ; or, Ci-C ⁇ alkyl optionally substituted with 1, 2, or 3 groups independently selected from halogen, or
  • R 105 and R' IOS together with the atom to which they are attached form a 3 to 7 membered carbocylic ring, where one member is optionally a heteratom selected from -0-, -S(0)o-2- > - N(Ri 35 )-, the ring being optionally substituted with 1, 2 or three R ⁇ 0 groups;
  • R1 80 is selected from morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S-oxide, homothiomorpholinyl S,S- dioxide, pyrrolinyl and pyrrolidinyl , each of which is optionally substituted with 1, 2, 3, or 4 groups independently selected from C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C ⁇ - C 6 ) alkylamino, di (C ⁇ -C 6 ) alkylamino, C-C 6 alkenyl, C 2 -C 6 alkynyl, Ci-C ⁇ haloalkyl, C ⁇ -C 6
  • C ⁇ -C 6 alkyl C 2 -C 6 alkenyl or C 2 -C6 alkynyl, each of which is optionally substituted with 1, 2, or 3 groups that are independently selected from C1-C 3 alkyl, halogen,
  • the invention provides compounds of Formula X where Ri is :
  • (V) C 2 -C 6 alkynyl with one or two triple bonds, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C ⁇ N, -CF 3 , C1-C3 alkoxy, -NR ⁇ _ a R ⁇ -b where R ⁇ _ a and R ⁇ _b are -H or C ⁇ -C 6 alkyl,
  • Ci-C ⁇ alkyl optionally substituted with one, two or three substituents selected from the group consisting of Ci- C 3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -NR ⁇ - a R ⁇ _ b , -C ⁇ N, -CF 3 , and C 1 -C 3 alkoxy
  • B C2-C 6 alkenyl optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C ⁇ N, -CF 3 , C1-C 3 alkoxy, and -NRi- a Rx- b ,
  • C C -C 6 optionally substituted with one, two or three substituents selected from the group consisting of -F, - Cl, -OH, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 3 alkoxy, and -NR
  • Ri-heteroaryi i selected from the group consisting of pyridinyl, pyrimidinyl, quinolinyl, benzothienyl, indolyl, indolinyl, pryidazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl
  • Ci-C ⁇ alkyl optionally substituted with one, two or three substituents selected from the group consisting of Ci- C 3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -NRi- a Ri- b , -C ⁇ N, -CF 3 , and C 1 -C3 alkoxy, (2) C2-C6 alkenyl with one or two double bonds, optionally substituted with one, two or three substituents selected from the group consisting of -F, -Cl, -OH, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 3 alkoxy, and -NR ⁇ _ a R ⁇ -b,
  • Ri-heterocycie is selected from the group consisting of morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl , piperidinyl, tetrahydrofuranyl, tetrahydrothienyl, homopiperidinyl, homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S,S- dioxide, oxazolidinonyl, dihydr
  • C 2 -C 6 alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C ⁇ N, -CF 3 , C1-C 3 alkoxy, and -
  • R is selected from the group consisting of: (I)-H, (II) C ⁇ -C 6 alkyl, optionally substituted with one, two or three substituents independently selected from the group consisting of C ⁇ -C 3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C ⁇ N, - CF 3 , C1-C3 alkoxy, and -NR ⁇ _ a R ⁇ -b, ( III ) - (CH 2 ) 0- 4 -R30 Where R30 is Ri-aryl , Rl-heteroaryl , Or R X - heterocycle
  • (V) C 2 -C 6 alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 3 alkoxy, and - NRi-aRi-b,
  • R' and R" at each occurrence are the same or different and are -H or C 1 -C 4 alkyl
  • Rjsi-aryi wherein Ru-aryi at each occurrence is independently phenyl; naphthyl; tetralinyl; indanyl; indenyl; dihydronaphthyl ; or 6, 7 , 8, 9-tetrahydro-5H- benzo [a] cycloheptenyl; each of which is optionally substituted with 1, 2, or 3 groups that at each occurrence are independently:
  • C ⁇ -C 6 alkyl optionally substituted with one, two or three substituents selected from the group consisting of C ⁇ -C 3 alkyl, -F, -Cl, -Br, -I,
  • R ⁇ a and Ri_ b at each occurrence are independently H or C ⁇ -C 6 alkyl
  • R N _ 2 and R N _ 3 are the same or different and are selected from the group consisting of:
  • R N _2, R N - 3 and the nitrogen to which they are attached form a 5, 6, or 7 membered heterocycloalkyl or heteroaryl group, wherein said heterocycloalkyl or heteroaryl group is optionally fused to a benzene, pyridine, or pyrimidine ring, and said groups are unsubstituted or substituted with 1, 2 , 3 , 4 , or 5 groups that at each occurrence are independently Ci-C ⁇ alkyl, C ⁇ -C 6 alkoxy, halogen, halo C ⁇ -C 6 alkyl, halo C ⁇ -C 6 alkoxy, -CN, -N0 2 , -NH 2 , NH(C ⁇ -C 5 alkyl), N(C ⁇ -C 6 alkyl) (C ⁇ -C 6 alkyl), -OH, -C(0)NH 2 , -C (0)NH(C ⁇ -C 6 alkyl), -C(0)N(d-C 6 alkyl) (C
  • R N -heteroaryi is selected from the group consisting of pyridinyl, pyrimidinyl, quinolinyl, benzothienyl, indolyl, indolinyl, pryidazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzisothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxazolopyridinyl, imidazopyridinyl, iso
  • R N _ 8 at each occurrence is independently -H, C ⁇ -C 6 alkyl or -phenyl which is optionally substituted with 1 or 2 groups that are independently halogen, C ⁇ -C 4 alkoxy, C 1 -C4 alkyl or -C(0)NH 2 ,
  • R N _ ⁇ o is selected from the group consisting of:
  • R c is : (I) -Ci-Cio alkyl optionally substituted with one, two or three substituents selected from the group consisting of C1-C3 alkyl, -F, -Cl, -Br, -I, -OH,
  • cycloalkyl can be optionally substituted with one, two or three substituents independently selected from the group consisting of C ⁇ -C 3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 6 alkoxy, -0- phenyl, -C0 2 H, -C0 2 - (C 1 -C4 alkyl), and -NR ⁇ _ a R ⁇ _ b ,
  • (III) - (CR c - ⁇ Rc-y) 0-4-Rc-aryi at each occurrence is independently phenyl; naphthyl; tetralinyl; indanyl; indenyl; dihydronaphthyl or 6,7,8, 9-tetrahydro-5H- benzo [a] cycloheptenyl ; each of which is optionally substituted with 1, 2, or 3 groups that at each occurrence are independently:
  • Ci-C ⁇ alkyl optionally substituted with one, two or three substituents selected from the group consisting of Ci-
  • C -C 6 alkenyl, C 2 -C 6 alkynyl, and phenyl , or Rc- ⁇ and R- y are taken together with the carbon to which they are attached to form a carbocycle of three, four, five, six and seven carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of -0-, -S-, -SO2-, -NR N - 2 - and R-aryi is defined as is defined above; (IV) - (CR C - ⁇ Rc-y) ⁇ -4-Rc-heteroaryl Where Rc-heteroaryl at each occurrence is independently selected from the group consisting of pyridinyl, pyrimidinyl , quinolinyl, benzothienyl, indolyl, indolinyl, pryidazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl
  • Rc-heterocycie i selected from the group consisting of morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, piperazinyl, homopiperazinyl , pyrrolidinyl , pyrrolinyl, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl , tetrahydrothienyl, homopiperidinyl , homomorpholinyl, homothiomorpholinyl, homothiomorpholinyl S,S- dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl , dihydropyrazinyl, dihydropyridinyl, dihydropyrimidiny
  • Ci-C ⁇ alkyl optionally substituted with one, two or three substituents independently selected from the group consisting of C ⁇ -C 3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -NR ⁇ _ a R ⁇ - b , -C ⁇ N, -CF 3 , and C1-C 3 alkoxy,
  • C 2 -C 6 alkynyl optionally substituted with one, two or three substituents independently selected from the group consisting of -F, -Cl, -OH, -SH, -C ⁇ N, -CF 3 , C 1 -C 3 alkoxy, and -
  • (B) -C ⁇ -C 6 alkyl optionally substituted with one, two or three substituents selected from the group consisting of C 1 -C 3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 6 alkoxy, -O-phenyl, and -NR ⁇ _ a R ⁇ ,
  • R c -5 is C ⁇ -C 6 alkyl
  • R C - 3 at each occurrence is the same or different and is :
  • (XX) C-C ⁇ o alkenyl optionally substituted with one, two or three substituents selected from the group consisting of C ⁇ -C 3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 6 alkoxy, -0- phenyl, and -NR ⁇ _ a R ⁇ -b,
  • (XXI) C 2 -C ⁇ o alkynyl optionally substituted with one, two or three substituents selected from the group consisting of Ci- C 3 alkyl, -F, -Cl, -Br, -I, -OH, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 6 alkoxy, -O-phenyl, and -NR ⁇ _ a R ⁇ -b,
  • R 25 at each occurrence is independently selected from the group consisting of hydrogen, Ci-C ⁇ alkyl, C ⁇ -C 6 alkoxy, Ci-C ⁇ alkoxy C ⁇ -C 6 alkyl, hydroxy C ⁇ -C 6 alkyl, halo Ci-C ⁇ alkyl, Ci-C ⁇ alkanoyl, each of which is unsubstituted or substituted with 1, 2, 3, or 4 groups independently selected from halogen, alkyl, hydroxy, alkoxy, and NH 2 , and -R26-R27, wherein
  • R 26 is selected from the group consisting of -C(O)-,
  • R 27 is selected from the group consisting of alkyl, alkoxy, phenyl, pyridyl, and cyclopropyl, and pharmaceutically acceptable salts thereof.
  • a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's disease, for treating patients with mild cognitive impairment (MCI) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type,
  • Degenerative dementias including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, or diffuse Lewy body type of Alzheimer's disease and who is in need of such treatment which comprises administration of a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof .
  • the invention also discloses pharmaceutial compositions comprising compounds of the invention.
  • the invention provides compounds, compositions, kits, and methods for inhibiting beta-secretase-mediated cleavage of amyloid precursor protein (APP) . More particularly, the compounds, compositions, and methods of the invention are effective to inhibit the production of A beta peptide and to treat or prevent any human or veterinary disease or condition associated with a pathological form of A beta peptide. The compounds, compositions, and methods of the invention are useful for treating humans who have Alzheimer's Disease
  • AD Alzheimer's disease
  • MCI mild cognitive impairment
  • AD Alzheimer's disease
  • AD Alzheimer's disease
  • AD dementia associated with Parkinson's disease
  • MCI mild cognitive impairment
  • AD dementia associated with cortical basal degeneration
  • AD diffuse Lewy body type
  • the compounds of the invention possess beta-secretase inhibitory activity.
  • the inhibitory activities of the compounds of the invention are readily demonstrated, for example, using one or more of the assays described herein or known in the art .
  • R 30 is selected from the group consisting of phenyl, pyrazolopyrimidinyl, oxa-aza-benzoazulenyl, isoxazolyl, triazolopyridinyl, pyrrolidinonyl, tetrahydrothia-aza- fluorenyl , pyridyl , piperidinyl , dihydrocyclopentaquinolinyl, furyl, naphthothienyl, phthalazinonyl, thiadiazolyl, thienopyrimidinonyl , oxa- diaza-cyclopentanaphthalenyl , dihydrobenzodioxepinyl , chromanonyl, chromenonyl, oxazolidinyl, benzophenone, pyrazinyl mono N-oxide, benzofuranyl, pyrazolyl, -isoxazolyl-phenyl, phenyl
  • Ci-Cio alkyl optionally substituted with 1 phenyl or 1 CN; OH, hydroxy C ⁇ -C ⁇ 0 alkyl optionally substituted with phenyl or (C 1 -C 4 alkyl ) phenyl , C ⁇ -C 6 alkoxy optionally substituted with 1 or 2 groups that are independently hydroxy or phenyl; haloalkyl, haloalkoxy, (CH 2 ) 0 ⁇ 4 C (0)NR 3 ⁇ R 32 , -NR 3i -S0 2 - (C ⁇ -C 6 alkyl) wherein the alkyl group is optionally substituted with 1, 2, or 3 groups that are independently halogen or R 33 , -S0 2 - NH(C ⁇ -C 6 alkyl) wherein the alkyl group is optionally substituted with 1 or 2 groups that are independently halogen, OH, alkoxy, or R 33 ; - (C ⁇ -C 6 alkyl) -S0 2 - (
  • R33 at each occurrence is independently, H, NH , NH(C ⁇ -C 6 alkyl), N(C ⁇ -C 6 alkyl) (C ⁇ -C 6 alkyl), N(C ⁇ -C 6 alkyl) (phenyl) , N(C ⁇ -C 6 alkyl) (benzyl) ;
  • R35 is phenyl, C -C 8 cycloalkyl, -S-phenyl, benzodioxole, thienyl, C ⁇ -C 6 alkyl, furanyl, imidazolyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C 1 -C 4 alkyl, C 1 -C 4 alkoxy, OH, hydroxy C ⁇ -C 6 alkyl, halogen, halo C ⁇ -C 6 alkyl, halo C ⁇ -C 6 alkoxy, -0- (C ⁇ -C 6 alkyl ) -phenyl
  • R40 is phenyl, -phenyl-pyridyl, biphenyl, -phenyl-benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl-pyrimidinyl, phenyl-isoxazolyl, -C (0) -pyridyl, -(C 1 -C 4 alkyl) -0-C (O)NH- phenyl wherein the phenyl is optionally substituted with 1, 2, or 3 halogen atoms; - (C ⁇ -C 4 alkyl) -0-C (0)N(C ⁇ -C 6 alkyl ) -phenyl , - (C ⁇ -C 6 alkyl ) -phenyl , - (C ⁇ -C alkyl) -S0 2 NH 2 , -(C1-C4 alkyl) -S0 2 NH(C ⁇ -C 6 alkyl),
  • Preferred compounds of formula Zl include the compounds of formula Z2 :
  • R51 at each occurrence is independently Ci-C ⁇ alkyl, Ci-C ⁇ alkoxy, -NHS0- (C1-C4 alkyl) wherein the alkyl group is optionally substituted with 1, 2, or 3 halogens, -SO 2 -NH-
  • Preferred compounds of Z2 are those wherein ⁇ and R 42 are both hydrogen.
  • R 35 is phenyl, cyclohexyl,, -S-phenyl, benzodioxole, thienyl, C 3 -C 6 alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C1-C4 alkyl, C 1 -C 4 alkoxy, OH, hydroxy C ⁇ -C 6 alkyl, halogen, halo d-C 6 alkyl, halo C ⁇ -C 6 alkoxy, -0- (d-C 6 alkyl) -phenyl , -C0 2 - (C ⁇ -C 6 alkyl), -(C 1 -C 4 alkyl) - (C 5 -C 6 cycloalkyl).
  • R 35 is phenyl, cyclohexyl, -S-phenyl, benzodioxole, thienyl, C3- C ⁇ alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C 1 -C 4 alkyl, C1-C4 alkoxy, OH, hydroxy C ⁇ -C 3 alkyl, halogen, halo C ⁇ -C 6 alkyl, halo C ⁇ -C 6 alkoxy, -0- (C ⁇ -C 6 alkyl ) -phenyl , -C0 2 - (C ⁇ -C 6 alkyl), - (C1-C4 alkyl) - (C 5 -C 6 cycloalkyl); R 40 is phenyl, -phenyl-pyridine, biphenyl, -phenyl- benzothienyl, -phenyl-thi
  • R 42 is hydrogen or -CH 2 CN.
  • More preferred compounds of Z2 include those wherein
  • R 35 is phenyl, C 3 -C 8 cycloalkyl, -S-phenyl, benzodioxole, thienyl, C 3 -C 6 alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C 1 -C 4 alkyl, C1-C4 alkoxy, OH, hydroxy C ⁇ -C 6 alkyl, halogen, CF 3 , OCF 3 , -Obenzyl, -C0 2 - (Ci- C 6 alkyl), - (C1-C4 alkyl) - (C 5 -C 6 cycloalkyl);
  • R 40 is phenyl, -phenyl-pyridine, biphenyl, -phenyl- benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl- pyrimidinyl, -phenyl-isoxazolyl, -C (0) -pyridyl, - (C 1 -C4 alkyl) -0-C (O)NH-phenyl, - (C1-C4 alkyl) -0-C (O)N (C ⁇ -C 6 alkyl ) -phenyl , - (C 1 -C 4 alkyl ) -phenyl , - (C1-C4 alkyl ) -S0 2 NH 2 , -(C1-C4 alkyl) -S0 2 NH(C ⁇ -C 6 alkyl), - (C1-C4 alkyl) -S0 2 N(C ⁇ -
  • R 35 is phenyl; halophenyl, dihalophenyl; trihalophenyl ; tetrahalophenyl; pentahalophenyl; halo, benzyloxyphenyl; halo, alkylphenyl; benzyloxyphenyl; cyclohexyl; (C 1 -C4 alkoxy) carbonylphenyl ; (C 1 -C 4 alkoxy) phenyl; -S-phenyl, or benzodioxole; R 41 is H, cyclohexyl, phenyl, or C ⁇ -C 6 alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or C 1 -C 4 thioalkoxy; and R 42 is hydrogen or -CH 2 CN.
  • R 40 is phenyl, -phenyl-pyridine, biphenyl, -phenyl- benzothienyl, -phenyl-thienyl, -phenyl-furanyl, -phenyl- pyrimidinyl, -phenyl-isoxazolyl, - (C1-C4 alkyl) -0-C (O)NH- phenyl, - (C1-C4 alkyl) -0-C (0)N(C ⁇ -C 6 alkyl ) -phenyl , - (C 1 -C 4 alkyl) -S0 2 NH 2 , CN, - (C1-C4 alkyl) - (C 3 -C 6 cycloalkyl), - (C1-C4 alkyl) -C(0)0-(C ⁇ -C 4 alkyl), -(C1-C4 alkyl )-R 33 , or C ⁇ -C 8 alkyl,
  • R3 5 is 3 , 5-difluorophenyl; 3 , 5-dichlorophenyl; or 3-chloro, 5- fluorophenyl; and R4 0 is phenyl which is unsubstituted or substituted with 1, 2, or 3 groups that are independently fluoro, chloro, bromo, iodo, methyl, ethyl, methoxy, ethoxy, CF 3 , or -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 groups that are independently halogen, or -NHS0CH 3 .
  • R 51 at each occurrence is independently C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, -NHS0 2 CH 3 , -S0 2 -NH- (ethyl) -
  • R 31 and R 32 at each occurrence are independently selected from the group consisting of hydrogen, C ⁇ -C 6 alkyl, hydroxy C ⁇ -C 6 alkyl, - (CH 2 ) C (0)N (CH 3 ) 2 , CH 2 CH 2 N(CH 3 ) 2 , benzyl, phenethyl, -CH 2 CH 2 pyridyl , C(O) furanyl, or at each occurrence R 31 , R 32 and the nitrogen to which they are attached independently form a pyrrolidiny
  • Even more preferred compounds of Z2 are those wherein R 40 is 3-ethylphenyl or 3-methoxyphenyl; and R 42 is hydrogen.
  • Preferred compounds of Z2 include those wherein
  • R51 at each occurrence is independently C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, -C (0)NR 3 ⁇ R 32 , -C(0)CH 2 NH , cyclopentyloxy, NHC (O)NH (ethyl) , oxazole optionally substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl or phenyl , hydroxyethoxy, diethylaminoethoxy, wherein R3 1 and R 32 at each occurrence are independently selected from the group consisting of hydrogen, C ⁇ -C 6 alkyl, hydroxy Ci-C ⁇ alkyl, -CH 2 -tetrahydrofuran.
  • Other preferred compounds of Z2 include those wherein R 35 is cyclohexyl .
  • More preferred compounds include those wherein R 40 is phenyl, or C ⁇ -C 8 alkyl, wherein each is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo (Ci-
  • R 42 and R 41 are both hydrogen.
  • More preferred compounds include those wherein R 40 is phenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3- ethoxyphenyl, 4-ethoxyphenyl, 3-trifluoromethylphenyl, 4- trifluoromethylphenyl, 2-methylphenyl, 3-methylphenyl, 2- ethylphenyl, 3-ethylphenyl, or C 3 -C 6 alkyl; and
  • R 5 1 at each occurrence is independently d-C 6 alkyl, C ⁇ -C 6 alkoxy, or halogen
  • R i and R 3 2 at each occurrence are independently selected from the group consisting of hydrogen, C ⁇ -C 6 alkyl, hydroxy C ⁇ -C 6 alkyl, and - (d-C 6 alkyl)phenyl wherein the phenyl group is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C4 alkoxy, or halogen
  • R 31 , R 32 and the nitrogen to which they are attached independently form a pyrrolidinyl, piperazinyl, piperidinyl, or azepanyl, each of which is optionally fused to a benzene, pyridine or pyrimidine ring and each of which is optionally substituted with hydroxy, hydroxy Ci-C ⁇ alkyl, C1-C4 alkoxy C ⁇ -C 6 alkyl, -C
  • More preferred compounds include those wherein R 35 is 3 -halo, 5-benzyloxyphenyl; 3-benzyloxyphenyl; or 4- benzyloxyphenyl ; R 41 is H, cyclohexyl, phenyl, or C ⁇ -C 6 alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or C 1 -C 4 thioalkoxy; and R 42 is hydrogen or -CH 2 CN.
  • R 40 is phenyl, -phenyl-pyridine, biphenyl, - (C 1 -C4 alkyl) -0- C(0)NH-phenyl, - (C ⁇ -C alkyl) -0-C (0)N (C ⁇ -C 6 alkyl ) -phenyl , -(C1-C4 alkyl) -SO2NH2, - (C1-C4 alkyl) - (C 3 -C 6 cycloalkyl), - (C1-C4 alkyl) -C(0)0-(d-C 4 alkyl), - (C1-C4 alkyl) -R 33 , or Ci- C 8 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C4 alkoxy, CF 3 , -Obenzyl wherein the phen
  • More preferred compounds include those wherein R 40 is phenyl or C ⁇ -C 8 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, C 1 -C 4 alkyl, C1-C 4 alkoxy, CF 3 ,
  • R 4X is hydrogen or C ⁇ -C 6 alkyl optionally substituted with 1 or
  • R 4 is hydrogen
  • R51 at each occurrence is independently C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, -NHS0 2 - (C 1 -C 4 alkyl) wherein the alkyl group is optionally substituted with 1, 2, or 3 halogens, -SO 2 -NH-
  • More preferred compounds include those wherein R40 is phenyl or C ⁇ -C 8 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, C 1 -C4 alkyl, C 1 -C 4 alkoxy, or CF 3 ; and R 5i at each occurrence is independently C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, -NHS0 2 CH 3 , -NHS0 2 CF 3 , halogen, -CF 3 , OH, -S0 2 NR 3 ⁇ R 3 2, -C(0)NR 3 ⁇ R 32 , -NR31R32, hydroxy C1-C10 alkyl, hydroxy C1-C4 alkoxy, aminoalkoxy, NH (Ci-C ⁇ alkyl) -alkoxy, N(C ⁇ -C 6 alkyl) (C ⁇ -C 6 alkyl) -alkoxy, wherein R 3i and R 32 at
  • More preferred compounds include those wherein R 35 is 3-fluoro, 5-benzyloxyphenyl or 3-chloro, 5- benzyloxyphenyl .
  • More preferred compounds include those wherein R 35 is -S-phenyl, benzo [1, 3 ] dioxole, furanyl, or thienyl; R 41 is H, cyclohexyl, phenyl, or C ⁇ -C 6 alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or C 1 -C 4 thioalkoxy; and
  • R 42 is hydrogen or -CH 2 CN.
  • More preferred compounds include those wherein R40 is phenyl, -phenyl-pyridine, biphenyl, -phenyl-pyrimidinyl, -(C1-C4 alkyl) -0-C (O) NH-phenyl , - (C 1 -C4 alkyl) -0-C (0)N(C ⁇ -C 6 alkyl ) -phenyl , - (C1-C4 alkyl) -S0 2 NH 2 , - (C1-C4 alkyl) - (C 3 -C 6 cycloalkyl), - (C1-C4 alkyl) -C (0)0- (C1-C4 alkyl), - (C1-C4 alkyl )-R 33 , or C ⁇ -C 8 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, C 1 -C 4 alkyl, C 1
  • -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or -NHS0 2 - (C 1 -C4 alkyl), -NHS0 2 CF 3 .
  • Still more preferred compounds include those wherein R 40 is phenyl or C ⁇ -C 8 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C4 alkoxy, CF 3 , -Obenzyl wherein the phenyl is optionally substituted with 1 or 2 halogens, -CHO, or -NHS0 2 - (C 1 -C 4 alkyl); and
  • R 41 is hydrogen or Ci-d alkyl optionally substituted with 1 or 2 groups that are phenyl, hydroxy, or C1-C4 thioalkoxy; and; R 2 is hydrogen; and R 51 at each occurrence is independently C ⁇ -C 6 alkyl, Ci-C ⁇ alkoxy, -NHS0 2 - (C 1 -C 4 alkyl) wherein the alkyl group is optionally substituted with 1, 2, or 3 halogens, -S0 2 -NH- (C ⁇ -C 6 alkyl) -NH 2 , -S0 2 -NH- (C ⁇ -C 6 alkyl) -NH (C 1 -C 4 alkyl), - S0 2 -NH-(C ⁇ -C 6 alkyl) -N(C ⁇ -C alkyl) (C1-C4 alkyl), -NHC(0)NH 2 , -NHC(0)NH(C ⁇ -C 6 alkyl), -NHC (0)N(C-C 5 al
  • Still more preferred compounds include those wherein
  • R 40 is phenyl or C ⁇ -C 8 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or CF 3 ; and R 51 at each occurrence is independently C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, -NHS0 2 CH 3 , -NHS0 2 CF 3 , halogen, -CF 3 , OH, -S0 2 NR 3 ⁇ R 3 2, -C(0)NR 3 ⁇ R 3 2, -NR 3 ⁇ R 32 , hydroxy C1-C10 alkyl, hydroxy C 1 -C4 alkoxy, aminoalkoxy, NH (C ⁇ -C 6 alkyl) -alkoxy, N(C ⁇ -C 6 alkyl) (C ⁇ -C 6 alkyl) -alkoxy, wherein R 3 ⁇ and R 32 at each occurrence are
  • Particularly preferred compounds of Formula X are those where Ri is 3 , 5-difluorophenyl .
  • the invention provides compounds of formula Z3
  • R 30 is selected from the group consisting of phenyl, pyrazolopyrimidinyl , oxa-aza-benzoazulenyl, isoxazolyl, triazolopyridinyl, pyrrolidinonyl, tetrahydrothia-aza- fluorenyl, pyridyl, piperidinyl, dihydrocyclopentaquinolinyl, furyl , naphthothienyl, phthalazinonyl, thiadiazolyl, thienopyrimidinonyl, oxa- diaza-cyclopentanaphthalenyl , dihydrobenzodioxepinyl , chromanonyl, chromenonyl, oxazolidinyl, purinyl, oxaxolyl, thiazolyl, pyridazinonyl, thiazolyl, pyranyl, dihydropyranopyr
  • R 3i and R 32 at each occurrence are independently selected from the group consisting of hydrogen, C ⁇ -C 6 alkyl, hydroxy C ⁇ -C 6 alkyl, Ci-C ⁇ haloalkyl, - (C ⁇ -C 6 alkyl) -C(0)NH 2 , - (C ⁇ -C 6 alkyl) -C (O)NH (C ⁇ -C 6 alkyl), -
  • R 35 is phenyl, d-C 8 cycloalkyl, -S-phenyl, benzodioxole, thienyl, Ci-C ⁇ alkyl, furanyl, each of which is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently C1-C4 alkyl, C 1 -C 4 alkoxy, OH, hydroxy Ci-C ⁇ alkyl, halogen, halo C ⁇ -C 6 alkyl, halo Ci-C ⁇ alkoxy, -0- (C ⁇ -C 6 alkyl ) -phenyl , -C0 2 - (C ⁇ -C 6 alkyl), - (C 1 -C 4 alkyl) - (C 5 -C 6 cycloalkyl) ;
  • R 42 is H, Ci-Ce alkyl, benzyl, -NHC(O) - (C_.-C 6 alkyl), or -NHC(O)- phenyl wherein the phenyl is optionally substituted with 1 or 2 alkyl groups ,
  • R55 is cyclohexyl; cyclopentyl; azepanone; phenyl; piperidinyl;
  • C 6 alkyl) (d-C 6 alkyl); C ⁇ -C 6 alkoxycarbonyl ; -0- (C ⁇ -C 6 alkyl) -C(0)NR 31 R 32 ; - (C ⁇ -C 6 alkyl ) -phenyl ; 4, 5-dihydro-2H- pyridazin-3-one; C 5 -C6 cycloalkyl which is optionally substituted with one CN group, phenyloxy wherein the phenyl group is optionally substituted with -NHC(0)C ⁇ -C 6 alkyl, -N(d .
  • each ring is unsubstituted or substituted with 1, 2, or 3 groups that are independently OH, C ⁇ -C 6 alkyl, d-C 6 alkoxy, - (C ⁇ -C 6 alkyl) -imidazole wherein the imidazole is optionally substituted with 1 or 2 C 1 -C 4 alkyl groups, or hydroxy (C ⁇ -C 6 alkyl) wherein the alkyl group is optionally substituted with 1 phenyl ring, or
  • R 2 , R 55 and the nitrogen to which they are attached form a tetrahydroisoquinolinyl, dihydroisoquinolinyl, or isoquinolinyl group which is optionally substituted by 1, 2, 3, or 4 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, CN, OH, and phenyl, wherein the phenyl is optionally substituted with halogen, hydroxyl, C 1 -C 4 alkoxy, and C 1 -C 4 alkyl.
  • More preferred compounds of Z3 include those wherein R30 is selected from the group consisting of phenyl, pyrrolidinonyl, pyridyl, piperidinyl, furyl , cyclopropyl, and thienyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of C1-C10 alkyl, hydroxy, hydroxy C1-C10 alkyl Ci-C ⁇ alkoxy, -NR3 1 -SO2- (C ⁇ -C 6 alkyl), -S0 2 -NH (C ⁇ -C 6 alkyl), -S0 2 - N(C ⁇ -C 6 alkyl) (C ⁇ -C 6 alkyl), halogen, -NHC(0)NH 2 , -N(C ⁇ -C 6 alkyl )C(0)NH 2 , -N(C ⁇ -C 6 alkyl) C (O)NH (C ⁇ -C 6 alkyl
  • R55 is cyclohexyl; azepanone; phenyl; piperidinyl; -S0 2 -phenyl; pyrrolidinyl; or 4 , 5 , 6, 7-tetrahydro-thiazolo [5, 4- c] pyridine; wherein each is optionally substituted with - C(0)NH 2 ; C ⁇ -C 6 alkoxycarbonyl ; -0- (C ⁇ -C 6 alkyl) -C (0)NR 3 ⁇ R 32 ; -(Ci-C ⁇ alkyl ) -phenyl ; 4, 5-dihydro-2H-pyridazin-3-one; cyclopentyl which is optionally substituted with one CN group, phenyloxy wherein the phenyl group is optionally substituted with -NHC(0)d-C 6 alkyl, wherein R 31 , R 32 and the nitrogen to which they are attached form a pyrrolidine, piperidine, piperazine, or
  • R 42 , R 55 and the nitrogen to which they are attached form a tetrahydroisoquinolinyl, group which is optionally substituted by 1, 2, 3, or 4 groups that are independently halogen, C1-C4 alkyl, C1-C4 alkoxy, CN, OH, and phenyl, wherein the phenyl is optionally substituted with halogen, hydroxyl, C1-C4 alkoxy, and C 1 -C 4 alkyl.
  • R 30 is selected from the group consisting of phenyl, pyridyl, or piperidinylwherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from the group consisting of C1-C10 alkyl, hydroxy, hydroxy C1-C10 alkyl C ⁇ -C 6 alkoxy, halogen, -SO2NR31R32, -C(O) -NR31R32, -NR31R32, -0-C 3 -C 6 cycloalkyl, -C(0)-(d-C 6 alkyl); wherein R 31 and R 32 at each occurrence are independently selected from the group consisting of hydrogen, C ⁇ -C 6 alkyl, hydroxy C ⁇ -C 6 alkyl, - (Ci-Ce alkyl) -NH 2 , - (C ⁇ -C 6 alkyl) -NH(C ⁇ -C 6 alkyl), - (
  • R 35 is phenyl, cyclohexyl, cyclopentyl, or -S-phenyl, , each of which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C 4 alkyl, C 1 -C 4 alkoxy,
  • CF 3 OCF 3 , halogen, -Obenzyl, -C0 2 - (C ⁇ -C 6 alkyl), - (C1-C4 alkyl) -(C 5 -C 6 cycloalkyl).
  • the invention provides compounds of formula X100:
  • Ri, R2, R 3 , and R 4 are independently selected from hydrogen, halogen, C ⁇ -C 6 alkyl, hydroxy, C ⁇ -C 6 alkoxy, halo(C ⁇ -C 6 ) alkyl, hydroxy (d-C 6 ) alkyl, halo(C ⁇ - C ⁇ ) alkoxy, thio (C ⁇ -C 6 ) alkyl, (C ⁇ -C 6 ) alkoxy (C ⁇ -C 6 ) alkyl, amino (C ⁇ -C 6 ) alkyl, mono (C ⁇ -C 6 ) alkylamino (Ci-C ⁇ ) alkyl, di (C ⁇ -C 6 ) alkylamino (C ⁇ -C 6 ) alkyl, - (CH 2 ) 0 - 4 -aryl or - (CH)
  • R35 is phenyl, cyclohexyl, -S-phenyl, benzodioxole, thienyl, C 3 -
  • X and Y are independently selected from 0, NR 5 , C ⁇ 0) , CR ⁇ R 2 ,
  • R 5 is hydrogen, C ⁇ -C 6 alkyl, SO 2 R 5 ' , C(0)R 5 ' where R 5 ' is hydrogen, halogen, d-C 6 alkyl, hydroxy, C ⁇ -C 6 alkoxy, halo(C ⁇ -C6) alkyl, halo (C ⁇ -C 6 ) alkoxy, thio(C ⁇ -
  • C 6 ) alkyl (C ⁇ -C 6 ) alkoxy (C ⁇ -C 6 ) alkyl, amino (C ⁇ -C 6 ) alkyl, mono (Ci-C ⁇ ) alkylamino (d-C 6 ) alkyl, di (Ci-
  • C-C 6 alkenyl or C 2 -C 6 alkynyl each of which is optionally substituted with one, two or three substituents independently selected from the group consisting of halogen, hydroxy, -SH, cyano, -CF 3 , C 1 -C 3 alkoxy, amino, mono (C ⁇ -C 6 ) alkylamino, and di (Ci- C ⁇ ) alkylamino , -(CH 2 )o-4- C 3 -C 7 cycloalkyl, where the cycloalkyl is optionally substituted with ⁇ one, two or three substituents independently selected from the group consisting of halogen, hydroxy, -SH, cyano, -CF 3 , Ci- C 3 alkoxy, amino, mono (C ⁇ -C 6 ) alkylamino, and di (Ci- C 6 ) alkylamino; res phenyl or naphthyl, each of which is optionally substituted with 1-5 groups independently
  • R ⁇ 42 and R 144 independently re hydrogen, C ⁇ -C 6 alkyl, hydroxyl (C ⁇ -C 6 ) alkyl, amino (Ci-
  • R ⁇ 48 is selected from the group consisting of: C ⁇ -C 6 alkyl, - (CH 2 ) 0 - 2 - (Ri-aryi) , C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C cycloalkyl, and -(CH 2 ) 0 _ 2 - ( Rl-heteroaryl ) ,
  • q is 1.
  • two or three of R z , R z ', R z ' , and R z ' ' is hydrogen, and the other one or two of R z , R z ', R z ' ' , and R z ''' is hydroxy, nitro, halogen, -C0 2 H, cyano, or d-C 6 alkyl, where the alkyl is optionally substituted with one, two or three substituents independently selected from C 1 -C 3 alkyl, halogen, -OH, -SH, -C ⁇ N, -CF3 , C ⁇ -C 6 alkoxy, amino, mono (Ci-C ⁇ ) alkylamino, and di (C ⁇ -C 6 ) alkylamino .
  • Preferred compounds of formula X100 include those where three of R z , R z ' , R z '', and R z ' ' ' are hydrogen and the other is (Ci-Ce) alkyl, halogen, or (C ⁇ -C 6 ) alkoxy .
  • R ⁇ 40 is phenyl substituted with 1, 2, or 3 groups independently selected from C ⁇ -C 6 alkyl, optionally substituted with one, two or three groups independently selected from C 1 -C 3 alkyl, halogen, hydroxy, -SH, cyano, -CF 3 , C ⁇ -C 3 alkoxy, amino, mono (C ⁇ -C 6 ) alkylamino, and di (C ⁇ -C 6 ) alkylamino, hydroxy, nitro, halogen, -C0H, cyano, - (CH 2 ) 0-4-CO-NR142R144 where R ⁇ 42 and R144 independently re hydrogen, d-C 6 alkyl, hydroxy (C ⁇ -C 6 ) alkyl, amino (d- Ce) alkyl, and C 3 -C 7 cycloalkyl.
  • Still other preferred compounds of formula X100 include those where R ⁇ 40 is phenyl substituted with one of hydroxy, nitro, halogen, -C0 2 H, cyano, or C ⁇ -C 6 alkyl where the alkyl is optionally substituted with one, two or three groups independently selected from C 1 -C 3 alkyl, halogen, hydroxy, -SH, cyano, -CF 3 , C 1 -C 3 alkoxy, amino, mono (Ci-C ⁇ ) alkylamino, and di (C ⁇ -C 6 ) alkylamino; and one of - (CH 2 ) o-4-CO-NR ⁇ 2 Ri 4 4.
  • Other preferred compounds of formula X100 are those where R 140 is phenyl substituted with one of -C (0)NR ⁇ 42 R ⁇ 4 and R ⁇ 42 and R 144 are independently hydrogen or C ⁇ -C 6 alkyl .
  • More preferred compounds of formula X100 include those where Ri 42 and R 144 are the same and are propyl .
  • Preferred compounds of formula X100 include those where R 35 is phenyl substituted with 2 halogens.
  • Still other preferred compounds of formula X100 are those where R 35 is 3 , 5-difluorophenyl .
  • R14 0 is phenyl substituted with one of hydroxy, nitro, halogen, -C0 2 H, cyano, or Ci-C ⁇ alkyl where the alkyl is optionally substituted with one, two or three groups independently selected from C 1 -C 3 alkyl, halogen, hydroxy, -SH, cyano, -CF 3 , C 1 -C 3 alkoxy, amino, mono (C ⁇ -C 6 ) alkylamino, and di (C ⁇ -C 6 ) alkylamino; and one of -(CH 2 )o- 4 -CO-NR ⁇ 42 R ⁇ 44 .
  • Preferred specific compounds of formula X100 are those where R140 is phenyl substituted with one of -C (0)NRi 42 R 144 and R ⁇ 42 and R144 are independently hydrogen or d-C 6 alkyl .
  • Still other preferred compounds of formula X100 are those where the dashed lines all re single bonds .
  • Ri is hydrogen and X is S0 2 .
  • Y is methylene
  • More preferred compounds of X100 are those where Z' is 2- propyl.
  • X100 is those where Y is methylene and R 2 is hydrogen, hydroxy (C 1 -C3) alkyl , or (Ci- C 3 ) alkyl.
  • R group is methyl.
  • Ri is hydrogen;
  • X is S0 2 and Y is NR 5 , or X is NR 5 and Y is S0 2 , where each R 5 is hydrogen, (C ⁇ -C 6 ) alkyl , or hydroxy (C ⁇ -C 6 ) alkyl .
  • Ri is hydrogen
  • X is C(O) and Y is NR 5 , or X is NR 5 and Y is C(O), where each R 5 is hydrogen, (C ⁇ -C 6 ) alkyl, or hydroxy (Ci-C ⁇ ) alkyl .
  • Preferred compounds of formula X100 include those of formula X101
  • Preferred compounds of formula XlOO include those of formula XI03
  • Preferred compounds of formula X103 include those wherein R 2 is (C 1 -C3) alkyl.
  • Still other preferred compounds of formula X103 include those wherein R 2 is hydroxy (C 1 -C3) alkyl .
  • Preferred compounds of formula X104 include those wherein R 2 is (C 1 -C 3 ) alkyl.
  • the invention provides compounds of the formula Z4 :
  • Rioo is H, Ci-Cs alkoxycarbonyl, phenyl C ⁇ -C 6 alkyl, or phenyl Ci-C ⁇ alkoxycarbonyl;
  • Ruo is phenyl C ⁇ -C 6 alkyl, thienyl, -S-phenyl, furanyl, or benzodioxolyl, wherein each is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C 1 -C4 alkyl, C 1 -C 4 alkoxy, or phenyl C ⁇ -C 6 alkoxy;
  • R120 is H, phenyl C1-C6 alkyl, -d cycloalkyl optionally substituted with C -C 6 alky or phenyl, C 3 -Cs cycloalkyl Ci- C 4 alkyl, or C ⁇ -C 6 alkyl optionally substituted with -C (0)NRi2iRi22, wherein each of the above is optionally substituted
  • R121 and R122 are independently H, or C ⁇ -C 6 alkyl.
  • More preferred compound of Z4 inlcude those wherein Rioo is tertiary butoxy carbonyl. More preferred compound of Z4 inlcude those wherein Ruo is phenyl C ⁇ -C 6 alkyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or phenyl Ci- alkoxy.
  • More preferred compound of Z4 inlcude those wherein Ruo is monohalophenyl, dihalophenyl, or trihalophenyl .
  • More preferred compound of Z4 inlcude those wherein Ruo is thienyl, or -S-phenyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, benzyloxy.
  • More preferred compound of Z4 inlcude those wherein Ruo is furanyl, or benzodioxolyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C 1 -C 4 alkyl, C1-C4 alkoxy, benzyloxy.
  • More preferred compound of Z4 inlcude those wherein R ⁇ 0 is benzyl optionally substituted with 1, 2, or 3 groups that are independently Ci- alkyl, C 2 -d alkenyl, C 2 -d alkynyl, halogen, or Ci- alkoxy.
  • More preferred compound of Z4 inlcude those wherein R ⁇ 2 o is cyclopropyl optionally substituted with Ci- alky or phenyl; or cyclopropyl C 1 -C 4 alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently Ci-d alkyl, C 2 -d alkenyl, C 2 -d alkynyl, halogen, or C ⁇ -C 6 alkoxy.
  • R ⁇ 20 is H or benzyl optionally substituted with 1, 2, or 3 groups that are independently Ci- alkyl, C 2 -C 6 alkenyl, C 2 -d alkynyl, halogen, or Ci- alkoxy.
  • Ruo is phenyl Ci-d alkyl optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or phenyl C ⁇ -C 6 alkoxy; and R ⁇ 20 is cyclopropyl optionally substituted with Ci-d alky or phenyl; or cyclopropyl C1-C4 alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, or Ci- alkoxy.
  • Other even more preferred compound of Z4 inlcude those wherein
  • Ruo is thienyl, or -S-phenyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, benzyloxy; and R ⁇ 2 o is H or benzyl optionally substituted with 1, 2, or 3 groups that are independently C ⁇ -C 6 alkyl, -d alkenyl, C 2 -d alkynyl, halogen, or Ci-d alkoxy.
  • Ruo is thienyl, or -S-phenyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C4 alkyl, C 1 -C 4 alkoxy, benzyloxy; and R ⁇ 2 o is cyclopropyl optionally substituted with C ⁇ -C 6 alky or phenyl; or cyclopropyl C1-C4 alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently C ⁇ -C 6 alkyl, d-d alkenyl, C-d alkynyl, halogen, or Ci- alkoxy.
  • Ruo is furanyl, or benzodioxolyl each of which is optionally substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C1-C 4 alkyl, C ⁇ -C alkoxy, or benzyloxy.
  • Ri 20 is H or benzyl optionally substituted with 1, 2, or 3 groups that are independently C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, d-d alkynyl, halogen, or C ⁇ -C 6 alkoxy.
  • R 120 is cyclopropyl optionally substituted with Ci- alky or phenyl; or cyclopropyl C 1 -C 4 alkyl, wherein each of the above is optionally substituted with 1, 2, or 3 groups that are independently Ci- alkyl, d-d alkenyl, C 2 -d alkynyl, halogen, or Ci- alkoxy.
  • R 51 at each occurrence is independently H, -S0NH-propyl- OH, -S0 2 NH-ethyl-OH, -S0 2 NH-ethyl-OCH 3 , -S0 2 NH-CH(CH 3 ) 2 -CH 2 OH, -S0 2 NH-(CH 2 CH(OH)CH 3 ) , -S0 2 NH-ethyl-NH (CH 3 ) , -S0 2 NH (CH 2 CH 2 OH) 2 , -S0 2 NHCH(CH 3 )CH 2 OH, -S0 2 N(CH 3 ) , -S0 2 NH (CH 2 CH (OH) CH 3 ) , -S0 2 - pyrrolidine, -S0 2 - (2 , 6-dimethylpiperidine) , -S0 2 -(2- propylpiperidine) , -S0 2 - (hydroxypropyl) ,
  • R 5i groups are at the 3 and 5 positions of the phenyl group.
  • R 51 at each occurrence is independently selected from the group consisting of C1-C4 alkyl, -C(0)N(C ⁇ -d alkyl) (Ci-Cg alkyl), -C(0)NH 2 , -C(0)N(C 2 -C 6 alkenyl) (C 3 -C 8 cycloalkyl), -C(0)NH(C 3 -d cycloalkyl), -C (0)NH(C ⁇ -C 6 alkyl), C(O)- (pyrrolidine) optionally substituted with 1 or two groups that are independently alkoxyalkyl or hydroxy, halogen, -C(0)N(C ⁇ -d hydroxyalkyl) (C ⁇ -C 6 alkyl), -C (O)NH (alkoxyalkyl) ,
  • R 51 at each occurrence is independently selected from the group consisting of -S0 2 NH-propyl-OH, -S0 2 NH-ethyl-OH, -S0 2 NH-ethyl-OCH 3 , -S0 2 NH-CH (CH 3 ) 2 -CH 2 OH, -S0 2 NH- (CH 2 CH (OH) CH 3 ) , -S0 2 NH-ethyl-NH(CH 3 ) , -S0 2 NH (-CH 2 CH 2 OH) 2 , -S0 2 NHCH (CH 3 ) CH 2 0H, -S0 2 N(CH 3 ) 2 , -S0 2 NH(CH 2 CH(OH)CH 3 ) , -S0 2 -pyrrolidine, -S0 2 -(2,6- dimethylpiperidine) , -S0 2 - (2-propylpiperidine),
  • R30 is pyridyl which is unsubstituted or substituted with 1 or 2 groups that are independently selected from- the group consisting of C1-C4 alkyl, -C(0)N(d-C 6 alkyl) (C ⁇ -C 6 alkyl), -C(0)NH 2 , -C(0)N(C 2 -C 6 alkenyl) (C 3 -C 8 cycloalkyl), -C (0)NH(C 3 -C 8 cycloalkyl), -C (0)NH(C ⁇ -C 6 alkyl), C (0) - (pyrrolidine) optionally substituted with 1 or two groups that are independently alkoxyalkyl or hydroxy, halogen, -C(0)N(C ⁇ -C 6 hydroxyalkyl) (Ci-C 6 alkyl), -C (0)NH (alkoxyalkyl) , -C (0)N (alkoxyalkyl) (alkoxyalkyl) , -C(0)N(d
  • -C 6 alkyl C 2 -C 6 alkynyl, -S0 2 - (C ⁇ -C 6 hydroxyalkyl), -S0 2 NH(C ⁇ -C 6 hydroxyalkyl), -S0 2 N(C ⁇ -C 6 alkyl) (Ci-Ce hydroxyalkyl), - (C1-C4 alkyl) -S0 2 - (C1-C 4 alkyl), or -C (0) - (C1-C 10 alkyl).
  • R 30 is pyridyl which is unsubstituted or substituted with at least one group that is -S0 2 NH-propyl-OH, -S0 2 NH-ethyl-OH, -S0 2 NH-ethyl-OCH 3 , -S0 2 NH-CH (CH 3 ) 2 -CH 2 OH, -S0 2 NH- (CH 2 CH (OH) CH 3 ) , -S0 2 NH-ethyl-NH(CH 3 ) , -S0NH ( -CH 2 CH 2 OH) 2 , -S0 2 NHCH (CH 3 ) CH 2 OH, -S0 2 N(CH 3 ) 2 , -S0 2 NH(CH 2 CH(OH)CH 3 ) , -S0 2 -pyrrolidine, -S0 2 -(2,6- dimethylpiperidine) , -S0 2 - (2-propylpiperidine)
  • Ri is C 1 -C 4 alkyl, C -d alkynyl, or CF 3 ; R 2 and R 3 are both hydrogen; or
  • R 2 and R 3 and the carbon to which they are attached form a cyclopropyl ring;
  • R 4 is oxazolyl optionally substituted with methyl, thiazolyl,
  • R 5 is C1-C4 alkyl
  • Re is C 1 -C4 alkyl
  • X and Y are independently halogen; Z is CH or N.
  • Preferred compounds within Formula Z5 are those where Z is CH. Within this group, more preferred are those wherein R 2 and R 3 are both H.
  • Preferred compounds of Formula Z6 include those where Ri is ethyl, ethynyl or CF 3 ; and R 4 is 2-oxazolyl optionally substituted with methyl, 2-thiazolyl, ethynyl, or methyl, hereinafter compounds of Z6-1.
  • Preferred compounds of Z ⁇ -1 are those where R 5 is propyl; and R 6 is propyl. More preferably, Ri is ethyl; R4 is 2-oxazolyl optionally substituted with methyl; and X and Y are both F.
  • Z6-1 Other preferred compounds of Z6-1 are those where Ri is ethyl, or CF 3 ; and R 4 is 2-thiazolyl. More preferably, R 5 is propyl; and R 6 is propyl; or R 5 is methyl; and R 6 is propyl or butyl; and X and Y are both F. Still more preferable are compounds where Ri is ethyl. Particularly preferred compounds are those where R x is CF 3 ; R 5 is propyl; and R 6 is propyl.
  • Z6-1 Other preferred compounds of Z6-1 are those where Ri is ethynyl; and R4 is ethynyl, methyl, or 2-oxazolyl. More preferably, R 5 is propyl; and R 6 is propyl; and X and Y are both F. Even more preferred are compounds where R 4 is ethynyl or methyl .
  • Z7 Preferred compounds of Z7 are those where Ri is ethyl or ethynyl; R 4 is methyl or 2-oxazolyl, hereinafter compounds of formula Z7-1.
  • Preferred compounds of Z7-1 include those where R 5 and Re are both propyl; and X and Y are both F. More preferably, Z is N; and R 4 is methyl. Even more preferred are compounds of Z7-1 where Z is CH; and R 4 is methyl or 2-oxazolyl.
  • R 2 and R 3 are both hydrogen;
  • R f and R g are independently halogen
  • R 5 is C ⁇ -C 2 alkyl sulfonyl
  • R 6 is hydroxy (C1-C4) alkyl, preferably hydroxyethyl or (Ci- C ) alkoxy (C 1 -C4) alkyl, preferably methoxyethyl .
  • Yet other preferred compounds of the invention are those of formula Z9
  • Ri is C-C 3 alkyl
  • R 2 and R 3 are both hydrogen; or R f and R g are independently halogen;
  • R 5 and R 6 are independently C 3 -C 4 alkyl; or
  • R 5 is H and R 6 is d alkyl; or
  • R 5 , R 6 , and the nitrogen to which they are attached form a pyrrolidinyl ring optionally substituted with methoxymethyl; and R s is C ⁇ -C 2 alkyl, hydroxy (C 2 -C ) alkyl, N- [hydroxy (C 2 -C 4 ) alkyl] - N- (C ⁇ -C 2 ) alkylamino, N-methyl-N- (C 4 (t-butyl) alkyl) amino, -NH(C ⁇ -C 4 hydroxyalkyl), -N(C ⁇ -C 3 hydroxyalkyl) (C 1 -C 3 hydroxyalkyl), -N(C ⁇ -C 2 alkyl) (C ⁇ -C 2 alkyl), pyrrolidin-1- yl optionally substituted with hydroxymethyl or methoxymethyl, C ⁇ -C 2 alkoxy C 2 -C 3 alkyl, 1-piperazinyl , - NH 2 , -NH(C 2 -
  • Preferred compounds of formula Z9 include those where R s is N- [hydroxy (d-alkyl] -N-methylamino , -N(C ⁇ -C 3 hydroxyalkyl) (C1-C 3 hydroxyalkyl), or -NH(C ⁇ -C 4 hydroxyalkyl), hereinafter compounds of Z9-1.
  • Preferred compounds of formula Z9-1 include those where the hydroxyalkyl is 2-hydroxy-1, 1-dimethylethyl; 2- hydroxyethyl ; 3 -hydroxypropyl ; 1 (R) -2-hydroxy-1-methylethyl ; 1 (S) -2-hydroxy-l-methylethyl; 1 (S) -2-hydroxy-l-methylethyl; 2 (R) -2-hydroxypropyl; or 2 (S) -2-hydroxypropyl .
  • Preferred compound of formula Z9 include those wherein R s is 3-hydroxypropyl , 4-hydroxybutyl .
  • Other preferred compound of formula Z9 include those wherein R s is 2 (R) -2-methoxymethylpyrrolidin-l-yl, 2(R)-2- hydroxymethylpyrrolidin-1-yl, 2 (S) -2-hydroxymethylpyrrolidin-l- yl, pyrrolidin-1-yl or 1-piperazinyl, hereinafter Z9-1A.
  • R ⁇ is 2 (R) -2-methoxymethylpyrrolidin-l-yl , 2(R)-2- hydroxymethylpyrrolidin-1-yl , or 2(S)-2- hydroxymethylpyrrolidin-1-yl .
  • Still other preferred compound of formula Z9 include those wherein R 5 , R 6 , and the nitrogen to which they are attached form a 2 (S) -2-methoxymethyl)pyrrolidin-l-yl, hereinafter compounds of Z9-2.
  • Preferred compound of formula Z9-2 include those wherein R s is -NH (tert-butyl) , -N(CH 3 ) (CH 2 CH 3 ) , -N(CH 3 ) 2 , or 2(S)-2- methoxymethylpyrrolidin-1-yl , hereinafter Z9-3.
  • Preferred compounds of formula Z9 include those where R s is N- [hydroxy (d alkyl) ] -N-methylamino . Particularly preferred are those where Rs is N- (hydroxy-t-butyl) -N-methylamino .
  • hydroxy-t-butyl is meant a 1-Hydroxy-1-methyl-ethyl group.
  • Ri is ethyl or isopropyl. More preferably, Ri is ethyl.
  • Ri is C 2 -C 3 alkyl
  • R 2 and R 3 are both hydrogen
  • R f and R g are independently halogen
  • R 5 and R 6 are independently C 1 -C 4 alkyl
  • R d is C 1 -C2 alkyl (preferably methyl), N-hydroxy (C 2 -C 3 ) alkyl-N- (C1-C2) alkylamino, or C 1 -C2 alkylamino.
  • Zll or a pharmaceutically acceptable salt thereof, wherein X is nitrogen or CH;
  • R x is C2-C3 alkyl, amino, mono (C 1 -C3) alkylamino, di(C ⁇ -C 3 ) alkylamino, amino (C1-C3) alkyl, mono (C 1 -C3) alkylamino (Ci- d) alkyl, or di (C1-C3) alkylamino (C ⁇ -C 2 ) alkyl;
  • R2 and R3 are both hydrogen; or
  • R f and R g are both hydrogen or independently halogen;
  • R 5 and R 6 are independently methyl or C 2 -C 3 -C 4 alkyl, where at least one of R 5 and R 6 is not methyl .
  • Preferred compounds of Zll include those where at least one of R 5 and R 6 is d alkyl, hereinafter compounds of Zl-1. Even more preferred compounds of Zll are those where each of R 5 and R 6 is propyl.
  • Preferred compounds of Zll and Zll-1 are those where X is CH. More preferably, R x is di (C ⁇ -C 2 ) alkylamino . Even more preferred are those where at least one of R 5 and R 6 is propyl . Other preferred compounds of Zll-1 are those where X is nitrogen. More preferably, both of R5 and R 6 are not methyl. Other more preferred compounds of Zll-1 are those where Ri is di (C 1 -C 2 ) alkylamino (C 1 -C 2 ) alkyl . More preferably, the di(C ⁇ - C 2 ) alkylamino (C 1 -C 2 ) alkyl group is N,N-dimethyl- (C 1 -C 2 ) alkyl .
  • R 2 , R 3 , and the carbon to which they are attached form a cyclopropyl ring;
  • Rf and R g are independently halogen;
  • R 5 and R 6 are independently C 3 -d alkyl (more preferably, at least one of R5 and R 6 is propyl) ; and Rj is hydrogen or C 1 -C 2 alkoxymethyl .
  • Ri is C 2 -C 4 alkynyl, d-d alkyl preferably ethyl, isopropyl, or trifluoromethyl ;
  • R 2 and R 3 are both hydrogen; or R and R 3 together form a 3-membered ring with the carbon atom to which they are attached;
  • R f and R g are independently halogen;
  • R 5 and R 6 are independently C 3 -C4 alkyl; or one of R 5 and R 6 is methyl or ethyl and the other is C 3 or d, 5
  • Preferred compounds of formula Z13 include those where Ri is ethyl, n-propyl, isopropyl, or trifluoromethyl, more preferably ethyl or isopropyl. Even more preferred are compounds where R 5 and R 6 are independently propyl or butyl . Still more preferred are compounds where both of R 2 and R 3 are hydrogen. Particularly preferred are those wherein R f and R g are both chloro or fluoro.
  • Z13 preferred compounds of Z13 are those where Ri is ethyl or trifluoromethyl, hereinafter compounds of Z13-1.
  • R 5 is methyl, ethyl or propyl and
  • R 6 is C 3 -C 4 alkyl are more preferred. Even more preferred are those where R is propyl or butyl. Particularly preferred are those where R 6 is butyl and R 5 is methyl.
  • R 5 is methyl
  • Preferred compounds of Z13-2 include those where R f and R g are both chloro or fluoro. More preferably, both of R 2 and R 3 are hydrogen .
  • Ri is C 2 -C 3 alkynyl.
  • Still other preferred compounds of Formula Z13 are those wherein R 5 and R 6 are independently propyl or butyl, hereinafter Z13-3. More preferably, in compounds of Formula Z13-3, both of R and R 3 are hydrogen. Still more preferably,
  • R f and R g are both chloro or fluoro. Even more preferably, R and R 3 together form a 3-membered ring with the carbon atom to which they are attached.
  • Z14 or a pharmaceutically acceptable salt thereof, wherein one of X or X x is nitrogen or N + -0 " while the other is CH; Ri is C 2 -C 4 alkynyl, cyano, or C 1 -C 3 alkyl; R 2 and R 3 are both hydrogen; or
  • R 2 and R 3 together form a 3-membered ring with the carbon atom to which they are attached;
  • Rf and R g are independently halogen;
  • R p is hydrogen, C ⁇ -C 2 alkyl, or oxazolyl; and Rs and R ⁇ are independently C 3 -C 4 alkyl.
  • Preferred compounds of formula Z14 include those where X is nitrogen; Ri is C ⁇ -C 2 alkyl; R 2 and R 3 are hydrogen; and R p is hydrogen, C ⁇ -C 2 alkyl, or oxazol-2-yl.
  • Z14 preferred compounds of Z14 are those where X is nitrogen; Ri is C 2 -C 3 alkynyl; R and R 3 together form a 3- membered ring with the carbon atom to which they are attached; and R p is C 1 -C2 alkyl . Even more preferred are compounds where X is nitrogen; and R x is C alkynyl.
  • Z14 Other preferred compounds of Z14 are those where X is nitrogen; Ri is d-C 2 alkyl, preferably ethyl; R 2 and R 3 are hydrogen; and R p is hydrogen, C ⁇ -C 2 alkyl, or oxazol-2-yl. Still other preferred compounds of Z14 are those where X is nitrogen; Ri is C ⁇ -C 2 alkyl; R 2 and R 3 are hydrogen; and R p is hydrogen, C ⁇ -C alkyl, oxazol-2-yl, or cyano. More preferably, R p is cyano, methyl or oxazol-2-yl. Even more preferably, R p is methyl. Equally preferably, R p is oxazol-2-yl. Equally preferably, R p is cyano.
  • Yet other preferred compounds of Z14 are those wherein X is nitrogen; Ri is C 2 -C 3 alkyl; R and R3 together form a 3- membered ring with the carbon atom to which they are attached; and R p is C ⁇ -C 2 alkyl.
  • Preferred compounds of Z14 include those where R f and R g are both chloro or fluoro. Still other preferred compounds of Z14 are those where R 5 and R 6 are independently propyl or butyl . Yet still other compounds of Z14 include those wherein R f and R g are both chloro or fluoro, and R 5 and R 6 are independently propyl or butyl .
  • Still other compounds of formula Z14 include those wherein X is CH and X' is N. More preferably, Rp is is cyano, methyl or oxazol-2-yl. More preferably, R f and R g are both chloro or fluoro, and R 5 and R 6 are independently propyl or butyl. Equally preferably, compounds of Z14 include those wherein R 2 and R3 together form a 3-membered ring with the carbon atom to which they are attached. Still other preferred compounds of the invention are those of formula Z15
  • X and X' is nitrogen and the other is CH and Ri is C 2 -C alkyl or - (C ⁇ -C 2 alkyl) -N(C ⁇ -C 2 alkyl) (C ⁇ -C 2 alkyl) ; R f and R g are independently halogen; R p is C ⁇ -C 2 alkyl; and R 5 and R 6 are independently hydrogen or C3-C 4 (sec butyl) alkyl.
  • Preferred compounds of Z15 include those where X is nitrogen; X' is CH; and R 5 and R 6 are independently propyl or butyl.
  • Z15 are those where X is CH; X' is nitrogen; and R5 and R 6 are independently propyl or butyl. More preferably, i is -CH 2 N(CH 3 ) CH 3 , or ethyl. Still more preferably Ri is -CH 2 N (CH 3 ) CH 3 . Particularly preferred compounds of Z15 include those where one of R 5 and R 6 is hydrogen and the other is C butyl, more preferably sec-butyl.
  • R s is methylamino, ethylamino, d alkylamino, di (C 3 -alkyl) amino, or a group of the formula
  • R q is C1-C2 alkoxy (C ⁇ -C 2 ) alkyl ;
  • Ri is d-C 3 alkyl ; R 2 and R 3 are both hydrogen; and
  • R f and R g are independently halogen.
  • Z17 or a pharmaceutically acceptable salt thereof, wherein Z is CH 2 when the dashed line represents a single bond or CH or a nitrogen atom when the dashed line represents a double bond;
  • Ri is C 2 -C 3 alkyl, ; R and R 3 are both hydrogen; or
  • R 2 , R3 and the carbon to which they are attached form a cyclopropyl ring;
  • R f and R g are independently halogen;
  • Preferred compounds of formula Z17 include those where Rp is -N(CH 3 )S0 2 (C ⁇ -C 2 alkyl); and Ri is ethyl.
  • Z17 is CH 2 , hereinafter compounds of Z17-1.
  • Preferred compounds of Z17-1 include those where R p is N-(C ⁇ -d alkylsulfonyl) -N- ( (C 1 -C 3 ) alkyl) amino.
  • Z17 preferred compounds of Z17 are those where R j is methyl .
  • Still other preferred compounds of Z17-1 are those where R p is N- (methylsulfonyl) -N- ( (C ⁇ -C 2 ) alkyl) amino; and Rj is C 3 -C4 alkyl, preferably butyl, hereinafter Z17-2.
  • Preferred compounds of Z17-2 include those wherein R p is -N(CH 3 )S0 2 (C ⁇ -C 2 alkyl); and Ri is ethyl.
  • Z17 are those where R p is 2- oxazolyl .
  • Z is preferably CH 2 or CH. More preferably, Z is CH.
  • Z17 are those where R p is cyano; Z is CH 2 or CH; and Rj is C 3 -C 4 alkyl. Preferably, Z is CH and Rj is butyl.
  • Still other preferred compounds of Z17, Z17-1, and Z17-2 are those wherein at least one of Rf and Rg is fluorine. More preferably, both are fluorine.
  • Still other preferred compounds of Z17, Z17-1, and Z17-2 are those wherein R2 , R3 , and the carbon to which they are attached form a cyclopropyl ring.
  • Ri is C 2 -C 3 alkynyl, C ⁇ , -C 3 alkyl, amino, mono (C 1 -C 3 ) alkylamino, or di(C ⁇ -C 3 ) alkylamino, aminoalkyl, mono (Ci- d) alkylamino (C x -C 2 ) alkyl , di (C1-C 3 ) alkylamino (C ⁇ -C 2 ) alkyl , CF 3 , C1-C2 alkoxy, halogen, -NHS0 2 (d-C 2 alkyl); R 2 and R 3 are both hydrogen; or
  • R and R 3 together form a 3-membered ring with the carbon atom to which they are attached;
  • R f and R g are both hydrogen or independently halogen;
  • R 5 and R are independently d, 2 , 3 -C 4 alkyl; or one of R 5 and e is methyl or ethyl and the other is C 3 or C 4 alkyl, preferably butyl.
  • Preferred compounds of Formula Z18 include those where Ri is bromo or chloro.
  • Z18 preferred compounds include those of Z18-1, i.e., compounds of formula Z18 where Ri is C 2 -d alkyl.
  • Z18 preferred compounds include those of Z18-2, i.e., compounds of formula Z18 where Ri is di (C ⁇ -C 3 ) alkylamino and both of R f and R g are chloro or fluoro.
  • Still other pPreferred compounds of Z18 include those of Z18-3, i.e., compounds of formula Z18 where R x is di (Ci- C ) alkylamino (C ⁇ -C 2 ) alkyl, and both of R f and R g are chloro or fluoro . More preferred compounds of formula Z18 include those where X is nitrogen; R f and R g are both fluoro; Ri is C 1 -C 3 alkyl; and R 2 and R 3 together form a 3-membered ring with the carbon atom to which they are attached.
  • Preferred compounds of Z18-1 include those where both X and X' are CH; and R f and R g are both chloro or fluoro, hereinafter compounds of formula Z18-1-A. More preferred compounds of Z18-1 and Z18-1-A are those where one of R 5 and R 6 is methyl or ethyl and the other is C 3 or C 4 alkyl, preferably butyl . Still other more preferred compounds of Z18-1 include compounds of formula Z18-1-B, i.e., compounds of Z18-1 where R 5 and R 6 are independently C 2 -d alkyl. Preferred compounds of Z18-1-B include those where R 5 is - alkyl and R 6 is ethyl.
  • Z18-1-A preferred compounds of Z18-1-A are those where one of R 5 and R 6 is methyl or ethyl and the other is d or C alkyl, preferably butyl. More preferably, one of of R5 and R 6 is methyl. Yet other preferred compounds of Z18-1-A are those where R 5 and R 6 are independently propyl or butyl .
  • Preferred compounds of formula Z18 are compounds of formula Z18-4, i.e., compounds of formula Z18 where Ri is C 2 alkynyl.
  • Preferred compounds of Z18-4 include those where both X and X' are CH; and Rf and R g are both chloro or fluoro.
  • Z18-4 include those wherein X is nitrogen and X' is CH 3 .
  • Z18-1-A preferred compounds of Z18-1-A are those where R 5 and R 6 are independently propyl or butyl .
  • Still other preferred compounds of Z18 include those compounds wherein Ri is CF 3 , or -NHS0 2 CH 3 ; R 2 and R 3 are both H; and R 5 and Re are independently d or C4 alkyl, hereinafter Z18- 5.
  • Z18-6 Yet still other preferred compounds of Z18 include those wherein X is CH and X' is nitrogen, hereinafter Z18-6.
  • Preferred compounds of any of the embodiments of Z18, Z18- 1-A, -1-B, Z18-2, Z18-3, Z18-4, Z18-5, Z18-6 are those where R 2 and R 3 together form a 3-membered ring with the carbon atom to which they are attached, hereinafter Z18-7. More preferred compounds of Z18-7 include those wherein at least one of R f and R g is fluoro. More preferably, both Rf and Rg are fluoro.
  • Ri is C 2 -C 3 alkyl, or C ⁇ -C 2 alkoxy;
  • R 2 and R 3 are both hydrogen;
  • R f and R g are independently halogen;
  • R s is C 3 -C 9 alkyl (preferably C3-C4 alkyl) , thiazolinyl or thiazolidinyl .
  • Preferred compounds of formula Z19 include those where R s is 2-thiazolidinyl or 2- thiazolinyl and Ri is d-d alkyl.
  • Other preferred compounds of Z19 are those where R s is methyl, propyl or, more preferably, t-butyl . Still more preferably at least one of Rf and Rg is fluoro. Even more preferably, Ri is also C-C 3 alkyl.
  • Ri is also Ci- d alkoxy. Even more preferably, Ri is methoxy.
  • Ri is d-d alkyl, CF 3 , or -NH(C 3 -C 6 cycloalkyl);
  • R 2 and R 3 are both hydrogen; or R 2 and R3 together with the carbon atom to which they are attached form a 3-membered ring;
  • R p is pyridyl, piperazinyl, amino, amino (Ci-dp) ) alkyl, mono (Ci- d) alkylamino (C 1 -C5) alkyl, di (C ⁇ -C ) alkylamino (Ci- C ( 4) 5 ) alkyl, mono (C 1 -C3) alkylamino, di (C1-C3) alkylamino, amino (C 3 -C ) alkynyl, mono (C ⁇ -C ) alkylamino (C 3 -C 4 ) alkynyl, di(C ⁇ -d) alkylamino (C3-C5) alkynyl, -N(C ⁇ -C 2 alkyl) -S0 2 (C1-C2 alkyl), -NH-S0 2 (C ⁇ -C 2 alkyl), -N(C ⁇ -C 2 alkyl) -S0 2 -thienyl, -N(C
  • Preferred compounds of Formula Z20 include those of formula Z20-1, i.e., compounds of Z20 where R5 and R 6 are both C 3 alkyl.
  • Other preferred compounds of Formula Z20 include those of formula Z20-2, i.e., compounds of Z20 where R 2 and R 3 are hydrogen . Still other preferred compounds of Z20 are compounds of formula Z20-3, i.e., compounds of Z20 where R 2 and R 3 together form a 3 -membered ring with the carbon atom to which they are attached.
  • Preferred compounds of Z20-1, -2, and -3 are those where R p is 4-pyridyl, 2-pyrimidinyl, 4-pyrazolyl, or 4-imidazolyl, more preferably R p is 4-pyridyl, hereinafter Z20-3A.
  • Other preferred compounds of formulas Z20-1, -2, and -3 are those where R p is diethylamino or dimethylamino , hereinafter Z20-3B.
  • Still other preferred compounds of formulas Z20-1, -2, and -3 are those R p is amino or Ci-d alkylamino, hereinafter Z20-3C.
  • Z20-1, -2, and -3 are those where R p is 1-piperazinyl, hereinafter Z20-3D. Still other preferred compounds of Z20-1, -2, and -3 include compounds where R p is amino (C 2 -C 4 ) alkyl where the amino is optionally mono substituted with C ⁇ -C 2 alkyl, hereinafter Z20-3E; or where R p is
  • Z20-3F SO2CF 3 , hereinafter Z20-3F.
  • R p is di (C ⁇ -C 2 ) alkylamino (C 3 -C 5 ) alkyl, more preferably, N,N- dimethylamino (C 3 -C 5 ) alkyl, hereinafter Z20-3G.
  • Particularly preferred compounds of Z20-1, -2, and -3 are those where R p is 3- (mono (C ⁇ -C 2 ) alkylamino)propyn-l-yl, hereinafter Z20-3H.
  • Other particularly preferred compounds of Z20 are those where R p is 3- (mono (C ⁇ -C ) alkylamino)propyn-1-yl, 3- (di (C ⁇ -C 2 ) alkylamino)propyn-l-yl, or 4-(di(C ⁇ -
  • Z20-3I C 2 ) alkylamino) propyn-1-yl
  • Other preferred compounds of Z20, Z20-1, -2, and -3 are those where R p is di (C ⁇ -C 2 ) alkylamino (C 3 -C5) alkyl; and R 5 and R 6 are both C 3 alkyl, hereinafter Z20-3J.
  • Still other preferred compounds of Z20, Z20-1, -2, -3, are those where R p is C 2 -C 3 alkynyl, hereinafter Z20-4. More preferably, R p is C alkynyl.
  • Z20, Z20-1, -2, -3, -3A to -3J and -4 include those wherein Ri is ethyl or isopropyl.
  • Ri is isopropyl. More preferably Ri is ethyl. More preferably, at least one of R f and R g is fluoro. Even more preferably, both are fluoro. Still more preferably, Rf and Rg are attached to the 3 and 5 positions of the phenyl ring (with position 1 being the point of attachment to the CH group.)
  • Ri is C 2 -C 3 alkynyl; R 2 and R 3 are both hydrogen;
  • R p is C 1 -C 3 alkyl
  • R f and R g are independently halogen
  • R 5 and R 6 are independently C 3 -C alkyl; or one of R 5 and R 6 is methyl and the other is d or C alkyl.
  • Preferred compounds of formula Z21 include those where one of R 5 and Rg is methyl and the other is butyl, herein after
  • Ri is C1-C2 alkyl, C 2 -C 4 alkynyl or C 3 (isopropyl) -C 4 alkyl; R and R 3 are both hydrogen; or
  • R 2 and R 3 together form a 3-membered ring with the carbon atom to which they are attached;
  • R f and R g are independently halogen;
  • R p is C 1 -C 3 alkyl or a group of the formula : R s S0 - where R s is
  • R 5 iR 6 iN- and R 51 and R 6 ⁇ independently represent hydrogen or C 1 -C 4 alkyl groups ; or a group of the formula :
  • R t is C ⁇ -C 2 alkoxy (C ⁇ -C 2 ) alkyl ; and R g is C 1 -C 3 alkoxy (C ⁇ -C 2 ) alkyl , C ⁇ -C 4 alkyl , -C (0) NH 2 , or H .
  • Preferred compounds of formula Z22 include those where Ri is C 2 alkynyl ; R 2 and R 3 together form a 3 -membered ring with the carbon atom to which they are attached; and R p is R ⁇ S0 2 -
  • R 2 and R 3 are hydrogen; and R p is R ⁇ S0 2 - where R s is C 3 -C 4 amino, preferably propyl, more preferably t- butylamino.
  • Still other preferred compounds of formula Z22 include those where Ri is C ⁇ -C 2 alkyl; R and R 3 are hydrogen; R p is C ⁇ -C 2 alkyl; and R q is C 3 -C 4 alkyl, preferably propyl or butyl.
  • Still other preferred compounds of formula Z22 include those where Ri is C1-C2 alkyl; R 2 and R 3 are hydrogen; R p is C ⁇ -C 2 alkyl; and R q is propoxy (C ⁇ -C 2 ) alkyl .
  • R x is C ⁇ -C 2 alkyl; R2 and R 3 are hydrogen; R p is C ⁇ -C 2 alkyl; and R q is methoxy (C ⁇ -C 2 ) alkyl .
  • R x is C ⁇ -C 2 alkyl; R2 and R 3 are hydrogen; R p is C ⁇ -C 2 alkyl; and R q is methoxy (C ⁇ -C 2 ) alkyl .
  • Other preferred compounds of formula Z22 include those where Ri is C ⁇ -C 2 alkyl; R 2 and R 3 together form a 3-membered ring with the carbon atom to which they are attached; R p is Ci- d alkyl; and R q is C 1 -C2 alkyl.
  • R2 and R 3 are hydrogen; R p is C 1 -C 2 alkyl; and R q is C ⁇ -C 2 alkyl.
  • Particularly preferred are compounds of Z22 where Ri is isopropyl .
  • R q is (R) -methoxymethyl, methyl, propyl, (S) -propyl, (R) ' - propyl, butyl, (R) -butyl, (S) -butyl, (R) -2-methoxymethyl, or (R) -2-methoxyethyl .
  • Z is oxygen, nitrogen, or sulfur
  • Ri is chloro, bromo, hydrogen or C ⁇ -C 2 alkyl
  • Rf and R g are independently halogen
  • R 5 and R 6 are independently C 3 -C 4 alkyl; or one of R 5 and R is methyl and the other is C 3 or C 4 alkyl.
  • Preferred compounds of Formula Z23 include those where Z is nitrogen; and Ri is C 1 -C 3 alkyl. Preferred compounds of formula Z23 are those where Ri is bromo, and Z is oxygen, hereinafter Z23-1. Other preferred compounds of formula Z23 are those wherein Z is nitrogen, hereinafter Z23-2. Still other preferred compounds of formula Z23 are those wherein Z is sulfur, hereinafter compounds of formula Z23-3.
  • Particularly preferred compounds of Z23, Z23-1, Z23-2, and Z23-3 are those where one of R5 and R 6 is methyl and the other is butyl. Equally preferred are those where at least one of R 5 and Rg is propyl. Still more preferably, R x is C ⁇ -C 3 alkyl. Even more preferably, Ri is C 2 -C 3 alkyl. Ri can also be ethyl.
  • Ri is C1-C2-C 3 alkyl,; R 2 and R 3 are both hydrogen; or R p is C 1 -C2 alkyl;
  • R f and R g are both hydrogen or independently halogen; and R 5 and R 6 are independently C 3 -C 4 alkyl .
  • Preferred compounds of formula Z24 include those where Ri is ethyl. More preferably, Rp is also methyl. Still more preferably, R f and R g are both halogen.
  • Z25 or a pharmaceutically acceptable salt thereof, wherein one of X and X' is nitrogen and the other is CH or CRi; Ri is Ci-d-d alkyl R and R 3 are both hydrogen; or R 2 , R 3/ and the carbon to which they are attached form a cyclopropyl ring; R p is C ⁇ -C 2 alkyl;
  • R f and R g are independently halogen; and R 5 and R 6 are independently C 3 -C4 alkyl.
  • Preferred compounds of Z25 include compounds where X is CH and X' is nitrogen. Particularly preferred compounds of formula Z25 include those where Ri is ethyl. Even more preferred is when R 2 and R 3 are both hydrogen. Other preferred compounds of the invention are those of formula Z26
  • R and R g are independently halogen
  • R 5 and Rg are independently C3-C4 alkyl.
  • Preferred compounds of formula Z26 include compounds of Z26 where Ri is 6- (C ⁇ C 2 ) alkoxypyridin-2-yl .
  • Still other preferred compounds of formula Z26 include compounds of Z26 where R is 5-formylthien-3-yl .
  • Other preferred compounds of formula Z26 include compounds where R s ⁇ is cyano.
  • Yet other preferred compounds of formula Z26 include compounds of Z26 where Ri is 5-cyanopyrid-3-yl .
  • compositions Z26 are those of formula Z26-1, i.e., compounds of Z26 where Ri is 6-halopyrid- 3-yl. Particularly preferred compounds of Z26-1 are those where halogen in Ri is fluoro or chloro.
  • Still other preferred compounds of formula Z26 are those wherein Ri is a thienyl group optionally substituted with R s ll, or R' s ll, cyclopentyl, cyclohexyl, oxazolyl, isoxazolyl optionally substituted with one or two C ⁇ -C 2 alkyl groups, phenyl, or thien-2-yl optionally substituted with CHO. More preferably, the unsubstituted thienyl group is a thien-3-yl or a thien-2-yl.
  • Other preferred compounds of the invention are those of formula Z27
  • Z27 or a pharmaceutically acceptable salt thereof wherein Z is , , pyridyl or the pyridyl N-oxide wherein the pyridyl or the pyridyl N-oxide is substituted with C(0)NR 5 R 6 , wherein
  • R 5 and Rg are independently C 3 -d alkyl; or R 5 is methyl or ethyl and Rg is C 3 alkyl; Ri is C 1 -C 3 alkyl or halogen; R and R 3 are both hydrogen; R s is C1-C 3 alkylsulfonyl, C 1 -C 3 alkylsulfonyl (C 1 -C 3 ) alkyl,
  • R f and R g are independently halogen.
  • Ri in compounds of formula Z27 is ethyl. More
  • R s is C 1 -C 3 alkylsulfonyl, C 1 -C 3 alkylsulfonyl (C 1 -C 3 ) alkyl, -NHS0 2 CH 3 , or -NCH 3 S0 2 CH 3 .
  • Other preferred compounds include those wherein Z is pyridyl substituted with C(0)NR 5 Rg, wherein R 5 and Rg are independently C 3 -C 4 alkyl; or R 5 is methyl or ethyl and Rg is C 3 alkyl. More preferably, R 5 and R 6 are propyl. Still more
  • Z is or the N-oxide thereof.
  • Other preferred compounds of the invention are those of formula Z28
  • R 2 and R 3 are both hydrogen
  • R 5 and R 6 independently represent (a) C 1 -C3 alkyl optionally substituted with phenyl and (b) phenyl optionally substituted with halogen; and R f and R g are independently halogen.
  • Preferred compounds of formula Z28 include those where R 5 is methyl optionally substituted with phenyl and Rg is phenyl.
  • R 5 is C ⁇ -C 2 alkyl and R ⁇ is 4-halophenyl, preferably 4- chlorophenyl .
  • X is nitrogen or N + -0 ⁇ ;
  • Ri is C 2 -d alkynyl or C 1 -C 3 alkyl; R and R 3 are both hydrogen; or
  • R 2 and R 3 together form a 3-membered ring with the carbon atom to which they are attached;
  • R f and R g are independently halogen
  • R p is hydrogen or C 1 -C 2 alkyl; and R 5 and R 6 are independently C3-C 4 alkyl.
  • Preferred compounds of formula Z29 include those where R x is ethyl. More preferred compounds of formula Z29 include those where X is nitrogen; R p is C ⁇ -C 2 alkyl (preferably methyl); and R x is ethyl. Other preferred compounds of the invention are those of formula Z30
  • Ri is hydrogen or C 1 -C 3 alkyl
  • R 2 and R 3 are both hydrogen
  • R p is C1-C2 alkyl
  • R f and R g are independently halogen; and R 5 and Rg are independently C 3 -C 4 alkyl.
  • R S 3i is C 1 -C 2 alkyl
  • R S 4i is Ci-Cg alkyl, allyl, cyano (C 1 -C 3 ) alkyl, (C 4 -
  • C 7 cycloalkyl, pyridyl (C 1 -C 3 ) alkyl, phenyl, phenyl (d . - C 3 ) alkyl, amino (C 1 -C 3 ) alkyl, mono (C 1 -C 3 ) alkylamino (Ci-
  • R s is CH 3 , -N(C ⁇ -C 2 alkyl ) phenyl , or -N(C 2 -C 3 alkyl) (C 3 -C 4 alkyl) ;
  • Ri is d-d alkyl;
  • R 2 and R 3 are both hydrogen; and
  • R f and R g are independently halogen.
  • Preferred compounds of formula Z31 include those where R s4 ⁇ is pyridylethyl or phenylethyl.
  • R s4 ⁇ is diethylamino (C ⁇ -C 2 ) alkyl, more preferably diethylaminomethyl .
  • Still other preferred compounds of Z31 are those where R S 4i is C 3 - 5 alkyl .
  • Particularly preferred compounds of formula Z31 include those where R s is (2-cyanoethyl) (methyl) amino .
  • Other particularly preferred compounds of formula Z31 include those where R s is (cyclohexyl) (methyl) amino.
  • R s4 ⁇ is Ci-Cg alkyl, allyl, cyano (C 1 -C 3 ) alkyl, (C-C 7 ) cycloalkyl, pyridyl (C 1 -C 3 ) alkyl , phenyl , or phenyl (C 1 -C 3 ) alkyl .
  • R s4 ⁇ is phenyl or cyclohexyl .
  • R s is -N(CH 3 ) phenyl, or -N (ethyl ) (C3-C4 alkyl).
  • Ri is C 2 -C 3 alkynyl or C 1 -C3 alkyl
  • R f and R g are independently halogen
  • R 5 and Rg are independently C1-C4 alkyl .
  • Preferred compounds of formula Z33 include those where R 5 and Rg are C 3 alkyl .
  • Other preferred compounds of formula Z33 include those where R 5 is methyl and Rg is alkyl.
  • Particularly compounds of formula Z33 include those where Ri is ethyl .
  • Other particularly preferred compounds of formula Z33 include those where R 5 and Rg are both propyl or R 5 is methyl and Rg is propyl, hereinafter Z33-1.
  • Still other preferred compounds of formula Z33 and Z33-1 include those wherein Ri is d-C 3 alkynyl (preferably d alkynyl) .
  • R ⁇ is C 1 -C 4 alkyl
  • R m is C 1 -C 4 alkyl
  • Ri is C 2 -C 3 alkyl
  • R 2 and R are both hydrogen
  • R f and R g are independently halogen.
  • Z34 or a pharmaceutically acceptable salt thereof, wherein R m is C 1 -C 4 alkyl; Ri is C2-C3 alkyl; R 2 and R 3 are both hydrogen; and R and R g are independently halogen; Z is S, S(O) , S(0) 2 , or 0 .
  • Preferred compounds of formula Z34 include those where Z is S or S(0). More preferably, Ri is d alkyl.
  • Z35 or a pharmaceutically acceptable salt thereof, wherein one of X and X' is CH and the other is N; Ri is C 2 -C4 alkynyl; amino (C 1 -C 3 ) alkyl, mono (C 1 -C 3 ) alkylamino (Ci- d) alkyl, or di (C 1 -C 3 ) alkylamino (C ⁇ -C 2 ) alkyl; R2 and R 3 are both hydrogen; or
  • R 2 and R 3 together form a 3-membered ring with the carbon atom to which they are attached;
  • Rf and R g are independently halogen;
  • R 5 and R 6 are independently C 1 -C3-C 4 alkyl.
  • Preferred compounds of formula Z35 include those where R 2 and R 3 together form a 3-membered ring with the carbon atom to which they are attached; X is N; and X' is CH, hereinafter Z35- 1.
  • Other preferred compounds of formula Z35 include those of formula Z35-1, i.e., compounds of Z35 where R 2 and R 3 are hydrogen; X' is N; and X is CH, hereinafter Z35-2. More preferred compounds of Z35, Z35-1, and Z35-2 include those where Ri is C 2 alkynyl . More preferably, Ri is also di (C 1 -C 3 ) alkylamino (C 1 -C 3 ) alkyl. Even more preferably, R x is dimethylamino (C ⁇ -C 2 ) alkyl .
  • R 2 and R 3 are both hydrogen
  • R f and R g are independently halogen
  • R p is hydrogen, cyano, C 1 -C3 alkyl, amino, N- (C 1 -C 3 alkylsulfonyl) -N- ( (C 1 -C 3 ) alkyl) amino, 2-oxazolyl, or 1- pyrrolyl optionally substituted in the 2 and 5 positions with C ⁇ -C 2 alkyl;
  • R a is C 1 -C 3 alkyl, H or trifluoromethyl; and
  • Rj is C 1 -C 5 alkyl.
  • Preferred compounds of Z36 include those where Rj is methyl or ethyl and R p is hydrogen, methyl, or ethyl.
  • Z37 or a pharmaceutically acceptable salt thereof, wherein X is nitrogen or N + -0 " ; Ri is C 2 -C 4 alkynyl, cyano, C 1 -C 3 alkyl, or CF 3 ; R 2 and R 3 are both hydrogen; or R 2 and R 3 together form a 3-membered ring with the carbon atom to which they are attached; R f and R g are independently halogen; R p is hydrogen, cyano or C1-C2 alkyl; and R 5 and Rg are independently C 1 -C 4 alkyl .
  • Preferred compounds of formula Z37 include those of formula Z37-1, i.e., compounds of Z37 where X is N.
  • Preferred compounds of Z37-1 include those where R p is cyano. More preferred compounds of Z37-1 are those where R 5 is methyl and Rg is C2-C 4 alkyl. Particularly preferred compounds of Z37-1 are those where R 6 is propyl.
  • R 2 and R 3 are also hydrogen.
  • Z37 Other preferred compounds of Z37 include those wherein Ri is C 2 -C 3 alkynyl, or d alkyl; and R p is methyl.
  • Still other preferred compounds of Z37 include those wherein Ri is CF 3 . More preferably, Rp is also methyl. Even more preferably X is CH.
  • R 2 and R 3 together with the carbon atom to which they are attached form a 3-membered ring;
  • R p is d-C 3 alkynyl or C1-C3 alkyl;
  • R f and R g are independently halogen;
  • R 5 and Rg are independently C 3 -C 4 alkyl, or R 5 is methyl and Rg is C 3 -C 4 alkyl.
  • Z38, Z38-1, and Z38-2 include those wherein R x is hydrogen and R 2 and R 3 are both hydrogen, hereinafter Z38-3.
  • Preferred compounds of Z38-3 include those wherein R 5 and Rg are both C 3 -C 4 alkyl. Even more preferably, both are C 3 alkyl.
  • Still other preferred compounds of Z38, Z38-1, and Z38-2 include those wherein R x is hydrogen and R 2 and R 3 form a 3- membered ring, hereinafter Z38-4.
  • Z38, Z38-1, and Z38-2 include those wherein R x is -CH 2 OH.
  • R 2 and R 3 are also hydrogen, hereinafter Z38-4A.
  • Z38-5 Even more preferred compounds of Z38 are those where Ri is hydrogen and R 2 and R 3 together with the carbon atom to which they are attached form a 3-membered ring, hereinafter Z38-5.
  • Preferred compounds of formula Z38-5 include those wherein R p is C 2 -C 3 alkynyl (preferably d alkynyl) or methyl. More preferably, at least one of R5 and Rg is C 3 alkyl. Still more preferably, R 5 is methyl or propyl and Rg is propyl, hereinafter Z38-5A.
  • Z38, Z38-l,Z38-2, Z38-3, Z38-4, Z38- 4A, Z38-5 and Z38-5A include compounds are those where R f and R g are both chloro or fluoro. Particularly preferred among Z38 compounds are those where R f and R g are both fluoro and are in the 3 and 5 positions with respect to the point of attachment of the phenyl group.
  • Ri is C2-C 3 alkyl
  • R2 and R 3 are both methyl or R 2 , R 3 , and the carbon to which they are attached form a cyclopropyl ring
  • R f and R g are independently halogen
  • R5 and Re are independently C 3 -d alkyl
  • R s is -NH(C ⁇ -C 4 hydroxyalkyl).
  • Preferred compounds of Z39 include those wherein the hydroxyalkyl group is 2-hydroxy-1, 1, dimethylethyl . More preferably, Ri is also ethyl.
  • R 2 and R 3 are both methyl. Equally preferably, R 2 , R 3 , and the carbon to which they are attached form a cyclopropyl ring.
  • Ri is C-d alkynyl; R and R 3 are both hydrogen; or R f and R g are independently halogen; R 5 and Re are independently C 3 -C 4 alkyl; and R s is -NH(C 2 -C hydroxyalkyl).
  • Preferred compounds of Z40 include those wherein the hydroxyalkyl group is 2-hydroxy-1, 1, dimethylethyl; or 2- hydroxyethyl .
  • R c is C4-C5 alkyl; cyclopropyl; tetrahydronaphthylenyl; -CH(C 2 alkyl-S-(C ⁇ -d) alkyl) C (O)NH (C 4 alkyl) ; -CH(C 2 alkyl-S0 2 - (d-C 2 ) alkyl )C(0)NH(C 4 alkyl); pyrimidyl optionally substituted with C3-C4 alkyl; thiochroman 1,1-dioxide; -CH 2 -thiazolyl optionally substituted with C 3 -C 4 alkyl, or -CH-isoxazolyl optionally substituted with C 1 -C 5 alkyl; R f and R g are independently halogen;
  • R p is -NHSO 2 CF 3 , -S0 2 NH(C 3 -C 4 hydroxyalkyl), -NHS0 2 CH 3 , oxazol-2- yl, or C 2 -C 4 alkynyl; and R 5 and R are independently C3-C4 alkyl.
  • Preferred compounds of Z41 include those wherein R c is C 4 -C 5 alkyl (preferably isobutyl or isopentyl) ; cyclopropyl; tetrahydronaphthylenyl; -CH(C 2 alkyl-S- (C ⁇ -C ) alkyl )C(0)NH(C alkyl); -CH(C 2 alkyl-S0 2 - (C ⁇ -C 2 ) alkyl) C (O)NH (C 4 alkyl); pyrimidyl optionally substituted with C 3 -d alkyl; thiochroman 1,1-dioxide; -CH 2 -thiazolyl optionally substituted with C 3 -C 4 alkyl, hereinafter Z41-1.
  • R c is C 4 -C 5 alkyl (preferably isobutyl or isopentyl) ; cyclopropyl; tetrahydronaphthylenyl;
  • More Preferred compounds of Z41-1 include those wherein R c is isobutyl; 1, 2 , 3 , 4-tetrahydronaphthylen-l-yl , -CH(CHCH 2 - S-CH 3 ) C (0)NH(C ⁇ -C 5 alkyl) where the alkyl group is preferably isobutyl, or 2-tert butylpyrimidin-4-yl, hereinafter Z41-2.
  • Z41 preferred compounds include those wherein R p is -S0NH(2-hydroxy-1, 1-dimethylethyl) , hereinafter z41-3.
  • Z41, Z41-1, Z41-2, and Z41-3 include those wherein R 5 and R 6 are both d alkyl .
  • Other preferred compounds of Z41 include those wherein R p is oxazol-2-yl; and R c is -CH 2 - (2-isobutylthiazol-5-yl) .
  • Still other preferred compounds of Z41 include those wherein R p is C -C 3 alkynyl (preferably d alkynyl) and R c is -CH- (2-isobutylthiazol-5-yl) .
  • Yet other preferred compounds of formula Z41 include those wherein R p is -CH 2 -isoxazolyl optionally substituted with C 1 -C 5 alkyl. More preferably, Rp is -CH 2 -isoxazol-5-yl . Even more preferably, it is -CH 2 - (3-isobutylisoxazol-5-yl) . Even more preferably R p is also C 2 -C 3 alkynyl. Still more preferably R 5 and R 6 are both C 3 alkyl.
  • Ri is C 2 -C 3 alkyl, or halogen; R 2 and R 3 are both hydrogen; or
  • R f and R g are independently halogen; and
  • R m is -NH-S0 2 CF 3 , oxazol-2-yl, -N(CH 3 ) S0 2 CH 3 , -N(C 3 -C4 hydroxyalkyl) S0 2 (C1-C2 alkyl), and R p is H; or
  • R m is H and R p is -NH-S0 2 CF 3 , -CH 2 S0 2 (C ⁇ -C 2 alkyl) where the alkyl group is preferably methyl; or R m is -C (0) pyrrolidinyl and R p is OH.
  • Preferred compounds of formula Z42 include those wherein R m is H and R p is -NH-S0 2 CF 3 , -CH 2 S0 2 (C ⁇ -C 2 alkyl), hereinafter Z42-1. Also preferred are compounds of Z42 wherein R m is -NH- SO2CF3, oxazol-2-yl, -N(CH 3 ) S0 2 CH 3 , -N(C 3 -C4 hydroxyalkyl) S0 2 (C x - C 2 alkyl), and R p is H, hereinafter Z42-2.
  • Preferred compounds of Z42, Z42-1, and Z42-2 include those wherein Rl is ethyl, bromo, or iodo. More preferred is when R 2 and R 3 are also both hydrogen;
  • Ri is d-d alkyl, C 3 -d cyanoalkyl, C 3 -C 6 alkenyl, -NHS0 2 (C ⁇ -C 2 alkyl), C 4 -C 5 haloalkyl, -C 3 alkyl-C0 2 - (C1-C2 alkyl), CN,
  • R 2 and R 3 are both hydrogen; Rf and R g are independently halogen; R p is C ⁇ -C 2 alkyl; R 5 and R 6 are independently C 3 -C 5 alkyl, C ⁇ -C 2 alkoxy C1-C 3 alkyl, or C 3 -C 5 alkenyl (preferably C 3 alkenyl) or R 5 is H and Rg is C-d alkyl or (C ⁇ C alkoxy) - (C 2 -C 3 alkyl),; R 5 is ethyl and R 6 is C 2 -C 3 hydroxyalkyl or -(C
  • Preferred compounds of formula Z43 include those wherein Ri is C-d alkyl, hereinafter Z43-1.
  • Ri is ethyl, isopropyl, isobutyl, sec-butyl, or isopentyl . More preferably ethyl or isopropyl. Still more preferably ethyl.
  • Z43-1A ethoxyethyl
  • R 5 is propyl
  • Rg is butyl
  • R 5 is ethyl and Rg is butyl (hereinafter Z43-1C) , R 5 is methyl or ethyl and Rg is -CH 2 - (cyclopropyl) , isobutyl, or C 2 -C 4 alkynyl (hereinafter Z43-1D) , or R 5 is ethyl and R 6 is propyl (hereinafter Z43-1E) , or R 5 is hydrogen and R 6 is sec-butyl (hereinafter Z43-1F) .
  • Z43 , Z43-1, Z43-1A, Z43- 1B, Z43-1C, Z43-1D, Z43-1E and Z431F are those wherein R p is methyl or C 2 alkynyl .
  • Still other preferred compounds of formula Z43 include those wherein Ri is cyclopentyl, cyclohexyl, propenyl, allyl, or -(C 3 -d alkyl) -CN, 4-chlorobutyl, 3-pyridyl, methyl 2- methylpropanoate, hex-5-enyl, CN, -N(CH 3 ) S0 2 CH 3 , -S0 2 CH 2 CH 3 , 3- methylpyrid-2-yl, oxazol-2-yl, 3 , 5-dimethylisoxazol-4-yl, 3- methylthien-2-yl, 2-pyridyl, 4-carbaldehydefuran-5-yl, and 2- carbaldehydethien-5-yl, 2-carbaldehyde-3-methylthien-5-yl, 2- methoxypyridin-4-yl, -NH-cyclopropyl, -NHS0CH 3 ; and R p
  • Preferred compounds of formula Z43- 2 include those wherein R 5 and Rg are also both d alkyl. Also preferred is when R 5 is ethyl and R 6 is butyl.
  • Preferred compounds of Z43, Z43-1, and Z43-2 include those wherein Ri is C 2 -C 3 alkynyl (preferably C 2 alkynyl) , hereinafter Z43-3.
  • Preferred compounds of Z43 , Z43-1, Z43-2, and Z43-3 include those wherein R 5 and Rg are independently C 3 -C 5 alkyl, C1-C2 alkoxy C 1 -C 3 alkyl.
  • R 5 and Rg are independently C 3 -C 5 alkyl, C1-C2 alkoxy C 1 -C 3 alkyl.
  • Z43-1, Z43-2, and Z43-3 include those wherein R 5 is H and Rg is C4, 5 -C 6 alkyl or (C ⁇ -C 2 alkoxy) - (C 2 -C 3 alkyl). Still other preferred compounds of Z43, Z43-1, Z43-2, and Z43-3 include those wherein R 5 is ethyl and R 6 is C 2 -C 3 hydroxyalkyl or - (C 1 -C 2 alkyl) -N(C ⁇ -C 2 alkyl) (C ⁇ -C 2 alkyl).
  • the -(C ⁇ -C 2 alkyl) -N(C ⁇ -C 2 alkyl) (C ⁇ -C 2 alkyl) is -(C ⁇ -C 2 alkyl) -N(CH 3 ) 2 .
  • Z43 , Z43-1, Z43-2, and Z43-3 include those wherein R 5 is CH 3 and R 6 is C 4 -C 5 alkyl, cyclohexyl, -(C ⁇ -C 2 alkyl) -phenyl , -(C ⁇ -C 2 alkyl) -pyridyl, or - CH 2 -furyl.
  • R 5 is CH 3 and R 6 is C4-C 5 alkyl, hereinafter Z43-4.
  • Still yet other preferred compounds of Z43, Z43-1, Z43-2, and Z43-3 include those wherein R 5 is methyl or ethyl and Rg is (C1-C2 alkoxy) - (C-C 3 alkyl).
  • Other preferred compounds of Z43 , Z43-1, Z43-2, and Z43-3 include those wherein R 5 , R 6 , and the nitrogen to which they are attached form a piperidinyl ring optionally substituted with C 3 -C 4 alkyl or OH, azepanyl, pyrrolidine-2-carboxylic acid amide, or 3-hydroxypiperidin-l-yl .
  • Further preferred compounds Z43, Z43-1, Z43-2, Z43-3, and Z43-4 include those wherein R p is methyl.
  • Ri is C 2 -C 3 alkyl, halogen, -NH(C 3 -C 6 cycloalkyl) preferably the cycloalkyl group is a cyclopropyl group, Rf and R g are independently halogen; R p is C1-C2 alkyl, oxazolyl, thiazolyl, or C 2 -C 3 alkynyl; R 2 , R 3 , and the carbon to which they are attached form a cyclopropyl ring; or R 2 and R 3 are both methyl;
  • Rs and Rg are independently C 3 -C 4 alkyl; or R 5 is methyl and R 6 is C 3 -C 5 alkyl.
  • Preferred compounds of formula Z44 inlude those wherein R 2 and R 3 are both methyl; and R5 and Rg are independently C 3 -C 4 alkyl, hereinafter Z44-1.
  • Preferred compounds of formula Z44 and Z44-1 include those wherein R p is oxazol-2-yl or thiazol-2-yl .
  • Preferred compounds of formula Z44 inlude those wherein R p is C -C 3 alkynyl; and R 5 and Rg are independently C 3 -C 4 alkyl.
  • Rl is bromo, chloro, or iodo or -NH (cyclopropyl) .
  • R c is isoxazolyl optionally substituted with C 3 -C 5 alkyl, thiazolyl optionally substituted with C 3 -d alkyl, or -Ci- C 3 alkyl-C(0)NH(Ci-C 3 alkyl);
  • Rf and R g are independently halogen;
  • R p is C 1 -C2 alkyl, oxazolyl, thiazolyl, or C 2 -C 4 alkynyl; R 5 and R 6 are independently C 3 -C 4 alkyl.
  • Preferred compounds of formula Z45 include those wherein R p is oxazol-2-yl or thiazol-2-yl, hereinafter Z45-1. More preferred compounds of Z45-1 include those wherein R c is 3- isobutylisoxazol-5-yl or N-isobutyl-2-methylpropion-2-yl amide; and R f and R g are independently Cl or F.
  • R c is 2-isobutylthiazol-2-yl
  • R f and R g are independently Cl or F.
  • Still other preferred compounds of formula Z45 include those wherein R c is 3-isobutylisoxazol-5-yl or N-isobutyl-2- methylpropion-2-yl amide; Rf and R g are independently Cl or F; and R p is C 2 -C 3 alkynyl.
  • Other preferred compounds of the invention are those of formula Z46
  • Hal is a halogen
  • Ri Ci-d alkyl, or halogen
  • R 2 and R 3 are both hydrogen
  • R f and R g are independently halogen
  • R z is C 1 -C2 alkyl
  • R 5 and R 6 are independently C 3 -C 4 alkyl.
  • Preferred compounds of formula Z45 include those wherein Hal is bromo or chloro. More preferably, Ri is also methyl, ethyl, bromo or iodo. More preferably Ri is methyl or ethyl. Even more preferably, it is ethyl.
  • Z47 n is 0 , 1 or 2 ;
  • Ri is C1-C2 alkyl
  • R 2 and R 3 are both hydrogen
  • Rf and R g are independently halogen
  • R s is (C1-C2 alkoxy) - (C ⁇ -C 2 alkyl) .
  • Preferred compounds of Z47 include those wherein R s is methoxymethyl.
  • n is 1.
  • Ri is Ci-d alkyl
  • R 2 and R 3 are both hydrogen; R f and R g are independently halogen;
  • R p is isoxazole optionally substituted with C ⁇ -C 2 alkyl
  • R 5 and R 6 are independently C3-C4 alkyl.
  • Preferred compounds of formula Z48 include those wherein
  • R p is 3-methylisoxazol-4-yl, 5-oxazolyl, 3-oxazolyl, 3- methyloxazol-2-yl, 3-ethyloxazol-2-yl .
  • Preferred compounds of Z ⁇ -Z 8 include those wherein at least one of R f and R g is fluoro. More preferably, both are fluoro. Even more preferably, R f and R g are in the 3 and 5 positions with respect to the point of attachment of the phenyl group .
  • the invention includes compounds of the formula Z49 :
  • R f and R g are both hydrogen or taken together with the carbon to which they are attached form a carbonyl;
  • X a is a covalent bond or a carbonyl;
  • R n is hydrogen or hydroxy;
  • Ri and R j are independently hydrogen or a halogen selected from
  • R k is -C ⁇ -6 alkyl
  • Ri is -C ⁇ _g alkyl or phenyl optionally substituted with Ci-Cg alkyl, Ci-d alkoxy, halogen, hydroxy, amino, mono (Ci- d) alkylamino, di (Ci-d) alkylamino, trifluoromethyl; and m is 0 or 1.
  • R f and R g preferably are taken together with the carbon to which they are attached to form a carbonyl
  • X a is preferably a covalent bond
  • R n is preferably hydrogen
  • m is preferably 1
  • Ri and Rj are preferably hydrogen.
  • R k is ethyl and R e is a meta- substituted ethyl phenyl group, -CH 2 CH 2 CH (CH3) 2 , methyl or phenyl.
  • Ri is preferably phenyl.
  • R f and R g are hydrogen
  • X a is a carbonyl
  • R h is hydroxyl
  • Ri and Rj are hydrogen and R k is ethyl.
  • R e is preferably a meta- substituted ethyl phenyl group, -CH 2 CH 2 CH (CH 3 ) 2 , or a methyl group .
  • R a is preferably methyl and R d is preferably ethyl
  • X is preferably 0, and R b and R c are preferably hydrogen.
  • R e is preferably a meta-substituted ethyl phenyl group, -CH 2 CH 2 CH (CH 3 ) 2 , methyl or phenyl.
  • X is preferably S
  • R b and R c are hydrogen
  • R e is a meta- substituted ethyl phenyl group or a methyl group.
  • R e is preferably phenyl .
  • the invention provides compounds of the formula Z50:
  • R a and Rd are C ⁇ _6 alkyl; X is 0 or S; R b and R c are independently hydrogen or a halogen selected from
  • R e is -C ⁇ _6 alkyl or phenyl optionally substituted with Ci-Cg alkyl, Ci-Cg alkoxy, halogen, hydroxy, amino, mono(C ⁇ -
  • the invention provides compounds of formula Z51:
  • B is aryl or heteroaryl optionally substituted with one or two groups independently selected from R 6 , R' 6 , R''e and R''' 6 , or B is cycloalkyl or heterocycloalkyl optionally substituted with one, two, three, four, five, six, seven or eight groups independently selected from Rg a , Rgb, R'g a , R' ⁇ b, R''6a,
  • C 2 -C alkenyl or C 2 -C 7 alkynyl each of which is optionally substituted with one, two or three substituents selected from the group consisting of halogen, -OH, -SH, -C ⁇ N, -CF 3 , C 1 -C 3 alkoxy, amino, mono- or dialkylamino, and Ci-d alkyl, or -(CH 2 )o-4 _ d-C 7 cycloalkyl optionally substituted with one, two or three substituents selected from the group consisting of halogen, -OH, -SH, -C ⁇ N, -CF 3 , C 1 -C 3 alkoxy, amino, mono- or dialkylamino, and Ci-d alkyl ; benzyl where the phenyl ring is optionally substituted with 1-3 groups independently selected from halogen,
  • C 2 -C 7 alkenyl or C 2 -C alkynyl each of which is optionally substituted with one, two or three groups independently selected from halogen or - OH, or C 2 -C 7 alkenyl or d-C 7 alkynyl, each of which is optionally substituted with one, two or three groups independently selected from halogen, C 1 -C3 alkyl, -OH, -SH, -C ⁇ N, -CF 3 , C 1 -C 3 alkoxy, amino, and mono- or dialkylamino, or - (CH 2 ) 0 - 4 -O- (Ci-Cg alkyl), where the alkyl portion is optionally substituted with one, two, three, four, or five of halogen, or any two of R 6a , R 6 b, R' ⁇ a, R'eb, R''ea, R''eb, R 7 , , 6a and R''eb together are o
  • -Ci-Cg alkyl optionally substituted with -OH or -NH 2 ; or; -Ci-Cg alkyl optionally substituted with one, two or three groups independently selected from halogen; or heterocyclyl optionally substituted with halogen, amino, mono- or dialkylamino, -OH, -C ⁇ N, -S0 2 -NH 2 , -S0 2 -NH- Ci-Ce alkyl, -S0 2 -N(d-C 6 alkyl) 2 , -S0 2 - (C 1 -C 4 alkyl), - CO-NH 2 , -CO-NH-Ci-Ce alkyl, oxo and -CO-N(d-C 6 alkyl ) 2 ; or
  • Ci-Cg alkyl optionally substituted with one, two or three groups independently selected from C 1 -C 3 alkyl, halogen, -OH, -SH, -C ⁇ N, -CF 3 , C 1 -C 3 alkoxy, amino, and mono- or dialkylamino; or
  • C-Cg alkenyl or C 2 -Cg alkynyl each of which is optionally substituted with one, two or three groups independently selected from C 1 -C 3 alkyl, halogen, -OH, -SH, -C ⁇ N, -CF 3 , C ⁇ -C 3 alkoxy, amino, and mono- or dialkylamino; or
  • Ci-Cg alkoxy optionally substituted with one, two or three of halogen; aryl or heteroaryl, each of which is optionally substituted with halogen, amino, mono- or dialkylamino, -OH, -C ⁇ N, -S0 2 -NH 2 , -S0 2 -NH-C ⁇ -C 6 alkyl, -S0 2 -N(C ⁇ -C 5 alkyl) 2 , -S0 2 - (C1-C4 alkyl), -CO- NH 2 , -CO-NH-Ci-C 6 alkyl, and -CO-N(d-C 6 alkyl) 2 ; or
  • Ci- alkyl optionally substituted with one, two or three groups independently selected from C 1 -C 3 alkyl, halogen, -OH, -SH, -C ⁇ N, -CF 3 , C 1 -C 3 alkoxy, amino, and mono- or dialkylamino; or C 2 -d alkenyl or C 2 -d alkynyl, each of which is optionally substituted with one, two or three groups independently selected from C 1 -C 3 alkyl, halogen, -OH, -SH, -C ⁇ N, -CF 3 , C 1 -C 3 alkoxy, amino, and mono- or dialkylamino; or Ci-C ⁇ alkoxy optionally substituted with one, two or three of halogen; Rio is heterocyclyl optionally substituted with one, two, three or four groups independently selected from Ci-Cg alkyl ; Ru is Ci-Cg alkyl, C-d alkenyl, C 2 -d alkynyl,
  • R ary ⁇ is aryl optionally substituted with halogen, amino, mono- or dialkylamino, -OH, -C ⁇ N, -S0 2 -NH 2 , -S0 2 -NH-C ⁇ -C 6 alkyl, -S0 2 -N(C ⁇ -C 6 alkyl) 2 , -S0 2 - (C1-C4 alkyl), -CO-NH 2 , -CO-NH-Ci- d alkyl, or -CO-N(C ⁇ -C 6 alkyl) 2 ; or Ci-Cg alkyl optionally substituted with one, two or three groups independently selected from C 1 -C 3 alkyl, halogen, -OH, -SH, -C ⁇ N, -CF 3 , C 1 -C 3 alkoxy, amino, and mono- or dialkylamino; or C -C 6 alkenyl or C 2 -d alkynyl, each of which is optionally
  • Ci-C ⁇ alkyl optionally substituted with one, two or three groups independently selected from C1-C3 alkyl, halogen, -OH, -SH, -C ⁇ N, -CF 3 , C 1 -C 3 alkoxy, amino, and mono- or dialkylamino; or C 2 -C 6 alkenyl or C 2 -Cg alkynyl, each of which is optionally substituted with one, two or three groups independently selected from C 1 -C 3 alkyl, halogen, - OH, -SH, -C ⁇ N, -CF 3 , C 1 -C 3 alkoxy, amino, and mono- or dialkylamino; or Ci-Cg alkoxy optionally substituted with one, two or three of halogen; Rheterocyciyi is heterocyclyl optionally substituted with halogen, amino, mono- or dialkylamino, -OH, -C ⁇ N, -S0-NH 2 , -S
  • R 2 and R 3 taken together with the carbon atom to which they are attached form a 3 or 4-membered ring;
  • R c is hydrogen or phenyl optionally substituted with C ⁇ -C 3 alkyl, d- alkynyl, trifluoromethyl, or C ⁇ -C 2 alkoxy.
  • the invention provides compounds of formula Z52 :
  • n 0, 1, 2, or 3 (preferably 1);
  • Ri is C 1 -C 3 alkoxy (preferably methoxy) , halogen (preferably iodo) , C ⁇ -C 3 alkyl (preferably ethyl or isopropyl), or C 2 - C 3 alkynyl (preferably C 2 alkynyl) ;
  • R and R g are independently halogen, or both are hydrogen; and Alk is Ci-Cg alkyl (preferably methyl, ethyl, isobutyl or isopentyl) .
  • Z52 include those wherein n is 1 and Ri is methoxy, C 2 alkynyl or ethyl. More preferably, Rl is methoxy.
  • the compounds of the invention inhibit beta-secretase and are therefor useful in treating and preventing Alzheimer's disease.
  • the compounds of the invention are made by methods well known to those skilled in the art from starting compounds known to those skilled in the art.
  • the process chemistry is well known to those skilled in the art.
  • the most general process to prepare compounds of the invention is set forth in CHART A.
  • amino acid (I) is protected at the amino group, yielding protected amino acid (II) .
  • Compound (II) is converted to an ester intermediate, and the intermediate is reacted with a carbon nucleofile yielding compound (III) .
  • the ketone moiety in compound (III) is reduced to yield alcohol (IV), which forms epoxide (V) .
  • the backbone of the compounds of the invention is a hydroxyethylamine moiety, -NH-CH (R) -CH (OH) - .
  • R hydroxyethylamine moiety
  • OH hydroxyethylamine -
  • CHART A sets forth a general method used in the invention to prepare the appropriately substituted amines (X) .
  • the compounds of the invention are prepared by starting with the corresponding amino acid (I) .
  • the amino acids (I) are well known to those skilled in the art or can be readily prepared from known compounds by methods well known to those skilled in the art.
  • the substituted amines (X) of the invention have at least two enantiomeric centers which give four enantiomers . The first of these enantiomeric centers derives from the amino acid starting material (I) . It is preferred to commercially obtain or produce the desired enantiomer (S) rather than produce an enantiomerically impure mixture and then have to separate out the desired enantiomer (S) . It is preferred to start the process with enantiomerically pure (S) -amino acid (I) of the same configuration as that of the substituted amine (X) product .
  • the first step of the process is to protect the free amino group of the (S) -amino acid (I) with an amino protecting group to produce the (S) -protected amino acid (II) by methods well known to those skilled in the art.
  • Amino protecting groups are well known to those skilled in the art. See for example, “Protecting Groups in Organic Synthesis”, John Wiley and sons, New York, N.Y. , 1981, Chapter 7; “Protecting Groups in Organic Chemistry", Plenum Press, New York, N.Y. , 1973, Chapter 2.
  • the function of the amino protecting group is to protect the free amino functionality (-NH 2 ) during subsequent reactions on the (S) -amino acid (I) which would not proceed well, either because the amino group would react and be functionalized in a way that is inconsistent with its need to be free for subsequent reactions, or the free amino group would interfere in the reaction.
  • the amino protecting group is no longer needed, it is removed by methods well known to those skilled in the art.
  • the amino protecting group must be readily removable as is known to those skilled in the art by methods well known to those skilled in the art.
  • Suitable amino PROTECTING GROUP is selected from the group consisting of t- butoxycarbonyl , benzyloxycarbonyl, formyl, trityl, acetyl, trichloroacetyl, dichloroacetyl, chloroacetyl, trifluoroacetyl, difluoroacetyl, fluoroacetyl, 4-phenylbenzyloxycarbonyl , 2- methylbenzyloxycarbonyl, 4-ethoxybenzyloxycarbonyl, 4- fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3- chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4- dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3- bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4- cyanobenzyloxycarbonyl , 2- ( 4-xenyl
  • the protecting group be t-butoxycarbonyl (BOC) and benzyloxycarbonyl (CBZ) , it is more preferred that the protecting group be t-butoxycarbonyl .
  • BOC t-butoxycarbonyl
  • CBZ benzyloxycarbonyl
  • the preferred methods of introducing a t- butoxycarbonyl or benzyloxycarbonyl protecting group and may additionally consult T.W. Green and P.G.M. Wuts in "Protective Groups in Organic Chemistry, " John Wiley and Sons, 1991 for guidance .
  • the (S) -protected compound (II) is transformed to a (S)- protected compound of formula (III) by first converting the
  • (S) -protected amino acid (II) to a corresponding alkyl ester according to methods well established in the art, for example by reaction with a diazocompound.
  • the ester inermediate is then reacted with a carbanionic nucleofile of those known to those skilled in the art, for example an organometallic compound obtained by reacting a compound of formula X ⁇ C(R 2 ) (R 3 )-X ⁇ with a strong metal base, wherein wherein the reaction yields a halogen-metal exchange, and wherein -Xi is a halogen selected from the group consisting of chlorine, bromine or iodine.
  • Suitable bases include, but are not limited to the alkyllithiums including, for example, sec-butyllithium, n- butyllithium, and t-butyllithium. Said reactions are preferably conducted at low temperature, for example -78 degrees C. Suitable reaction conditions include running the reaction in the presence of inert solvents or mixtures thereof, for example but not only ether, tetrahydrofuran or a mixture thereof.
  • R 2 and R 3 are both hydrogen
  • examples of Xi-C (R 2 ) (R 3 ) -Xi include dibromomethane, diiodomethane, chloroiodomethane, bromoiodomethane and bromochloromethane .
  • R and/or R 3 are not -H, then by the addition of -C(R 2 ) (R 3 )-X ⁇ to esters of the (S)- protected amino acid (II) to produce the (S) -protected compound (III) , an additional chiral center will be incorporated into the product, provided that R 2 and R 3 are not the same.
  • the (S) -protected compound (III) is then reduced by methods known to those skilled in the art for the reduction of ketones to the corresponding alcohol (IV) .
  • the reactants and reaction conditions for reducing the (S) -protected compound (III) to the corresponding alcohol (IV) include, for example, sodium borohydride, lithium borohydride, borane, dusobutylaluminum hydride, and lithium aluminium hydride.
  • Sodium borohydride is the preferred reducing agent.
  • the reduction is carried out for a period of time between 1 hour and 3 days at temperatures ranging from about -78 degrees C to the reflux temperature of the reaction mixture. It is preferred to conduct the reduction between about -78 degrees C and about 0 degrees C.
  • a borane complex may be used, for example, borane-methyl sulfide complex, borane-piperidine complex, or borane-tetrahydrofuran complex.
  • the preferred combination of reducing agents and reaction conditions needed are known to those skilled in the art, see for example, Larock, R.C. in Comprehensive Organic Transformations, VCH Publishers, 1989.
  • the reduction of the (S) -protected compound (III) to the corresponding alcohol (IV) produces the second chiral center (third chiral center if R 2 and R 3 are not the same) .
  • the reduction of the (S) -protected compound (III) produces a mixture of enantiomers at the second center, (S, R/S) -alcohol (IV) .
  • This enantiomeric mixture is then separated by means known to those skilled in the art such as selective low- temperature recrystallization or chromatographic separation, for example by HPLC, employing commercially available chiral stationary phases.
  • the enantiomer that is used in the remainder of the process of CHART A is the (S, S) -alcohol (IV) since this enantiomer is a precursor to the desired biologically active anti-Alzheimer (S, R) -substituted amine (X).
  • reaction conditions include contacting compound (IV) with a base, for example, but not limited to, sodium hydroxide, potassium hydroxide, or lithium hydroxide.
  • Reaction conditions include the presence of a C]_-Cg alcohol solvent; ethanol is preferred.
  • a common co-solvent for example ethyl acetate, may also be employed.
  • the reactions is preferably conducted at temperatures ranging from about -45 degrees C to the reflux temperature of the reaction mixture; preferred temperature ranges are between about -20 degrees C and about 20-25 degrees C.
  • the epoxide (V) is then reacted with the appropriately substituted C-terminal amine, R C -NH (VI) in reaction conditions known to those skilled in the art, leading to the opening the epoxide to yield the enantiomerically pure (S,R)- protected alcohol (VII) .
  • the substituted C-terminal amines, R C -NH 2 (VI) of this invention are commercially available or are known to those skilled in the art and can be readily prepared from known compounds. Further, it is preferred that when R c is phenyl, it is substituted in the 3-position or 3 , 5-positions .
  • Suitable reaction conditions for opening the epoxide (V) include running the reaction in an organic, preferably inert w. C ] _-C ⁇ alcohol solvents are preferred and isopropyl alcohol most preferred.
  • the reaction can be run at temperatures ranging from about 20-25 degrees C up to the reflux temperature of the reaction mixture and preferably at a temperature between about 50 degrees C and the reflux temperature of the reaction mixture.
  • the substituted C-terminal amine (VI) is a 1- amino-3 , 5-cis-dimethyl cyclohexyldicarboxylate it is preferrably prepared as follows. To dimethyl-5- aminoisophthalate in acetic acid and methanol, is added rhodium in alumina in a high-pressure bottle.
  • the bottle is saturated with hydrogen at 55 psi and shaken for one week of time.
  • the mixture is then filtered through a layer of diatomaceous earth and rinsed with methanol three times, the solvents are removed under reduced pressure (with heat) to give a concentrate.
  • the concentrate is triturated with ether and filtered again to give the desired C-terminal amine (VI) .
  • the substituted C- terminal amine (VI) is l-amino-3 , 5-cis-dimethoxy cyclohexane it is prepared by following the general procedure above and making non-critical variations but starting wth 3 , 5-dimethoxyaniline .
  • the substituted C-terminal amine (VI) is an aminomethyl group where the substituent on the methyl group is an aryl group, for example NH2-CH-Rc-aryi, and NH 2 -CH 2 -Rc-aryi is not commercially available it is preferrably prepared as follows .
  • a suitable starting material is the (appropriately substituted) aralkyl compound.
  • the first step is bromination of the alkyl substitutent via methods known to those skilled in the art, see for example R.C. Larock in Comprehensive Organic Transformations, VCH Publishers, 1989, p. 313.
  • the alkyl halide is reacted with azide to produce the aryl- (alkyl) -azide .
  • C-terminal amine (VI) of formula NH-CH 2 -Rc- ar yi-
  • the suitably functionalized C-terminal amines (VI) may readily be prepared by one skilled in the art via known methods in the literature, making non-significant modifications.
  • Select literature references include 1) Calderwood, et al . , Tet . Lett . , 1997, 38, 1241, 2) Ciganek, J. Org. Chem . , 1992, 57, 4521, 3) Thurkauf, et al . , J. Med . Chem . , 1990, 33 , 1452, 4) Werner, et al .
  • CHART B discloses an alternative process for the synthesis of the enantiomerically pure (S, R) -protected alcohol (VII) from the (S) -protected compound (III).
  • (S)- protected compound (III) is reacted with the appropriately substituted C-terminal amine R C -NH (VI) in the preferred reaction conditions described above to yield (S) -protected ketone (XI) which is reduced in the preferred conditions described above to yield (S, R) -protected alcohol (VII).
  • CHART C discloses another alternative process for the synthesis of enantiomerically pure (S, R) -protected alcohol
  • the (S,R) -protected compound (XIII)) is deprotected to yield (S,R) -amine (VII) by methods known to those skilled in the art for removal of amine protecting group. Suitable reaction conditions for the removal of an amine protecting group depend on the type of protecting group. For example, it is preferable to remove the preferred protecting group, BOC, by contacting (S, R) -protected alcohol (VII) with a mixture of and acid and an organic solvent, e.g. a trifluoroacetic acid/dichloromethane mixture, yielding the protonated salt of
  • (S,R)-amine (VII) can be purified by methods known to those skilled in the art, for example recrystallization.
  • the free-base (S,R) -amine (VII) can be obtained by means known to those skilled in the art, such as for example, preparing the free base amine by contacting the salt with mild basic conditions. Additional BOC deprotection conditions and deprotection conditions for other protecting groups can be found in T.W. Green and P.G.M. Wuts in "Protective Groups in Organic Chemistry, " John Wiley and Sons, 1991, p. 309.
  • Typical chemically suitable salts include trifluoroacetate, chloride, sulfate, phosphate; preferred is trifluoroacetate and chloride.
  • acylating reagent such as an anhydride, acyl halide, or acid of the formula (RN-1 _X N) 2° or R N-1 -X N -X 2 or R N-
  • R N is preferably selected from the group consisting of:
  • R N _1-X N - Wherein X N is -CO- , R N -i is R N - a ry l Or R N - h et e r o ar yl wherein R N -aryi is phenyl where the substitution on phenyl is 1 , 3 - , and wherein R N - ar yi or Ru-heteroaryi are substituted with one -
  • RN- 2 and R N _ 3 are preferably the same and are d alkyl, R N _ ⁇ -X N - wherein X N is -CO-, and R N _ ⁇ is R N -ary wherein R N - ary ⁇ is phenyl substituted with one -CO-NR N _ 2 R N _ 3 wherein the substitution on phenyl is 1,3-,
  • R N _ ⁇ -X N - wherein X N is-CO-, and R- ⁇ is Ru-aryi wherein R N -aryi is phenyl substituted with one Ci alkyl and with one -C0-NR N _ 2 R N - 3 wherein the substitution on the phenyl is 1,3,5-.
  • X N is preferably (A) -CO- and (B) -S0 2 -; more preferably X N is -CO-.
  • X 2 is selected from the group consisting of -Cl , -Br; more preferably, X 2 is -Cl .
  • reaction mixture is partitioned between saturated aqueous ammonium chloride and a water immiscible organic solvent, for example ethyl acetate.
  • aqueous layer is separated and extracted twice more with the organic solvent.
  • the organic extracts are combined and washed with a saturated aqueous solutions of bicarbonate and saline and dried over anhydrous sodium sulfate or magnesium sulfate.
  • the isophthalate ester or methylisophthalate ester of the mono-alkyl or di-alkyl amide iscontacted with an aqueous alkaline solution, for example lithium hydroxide in a minimum amount of THF/methanol/water and stirred 3-24 hours at 20 degrees C to the reflux temperature of the reaction mixture.
  • the solvents are then removed under reduced pressure and the products partitioned between water and a water immiscible solvent, for example ethyl acetate. If the formation of an emulsion hinders the separation of the two phases, a small amount of saline is added to aid the separation.
  • the aqueous phase is extracted once more with a water immiscible solvent, for example ethyl acetate.
  • the aqueous phase is then acidified via the addition of an acid, preferably hydrochloric acid, to pH ⁇ 3.
  • the resulting mixture is extracted three times with a water immiscible solvent, for example ethyl acetate.
  • the combined organic extracts are dried over anhydrous sodium or magnesium sulfate.
  • the drying agent is removed by filtration and the organic solvent is removed under reduced pressure to yield the product.
  • the mono- or di-alkyl amide isophthalate/methylisophthalate is reacted with (S,R) -amine (VIII) to produce the (S, R) -substituted amine (X). If R N - 2 and R N _ 3 are both -H, the following method is preferred.
  • An ester preferably the methyl ester of isophthalate or methyl 5-methyl-1, 3-isophthalate is dissolved in an organic solvent or a mixture of organic solvents, preferably a THF/DMF mixture.
  • CDI is added at about 20-25 degrees C.
  • ammonia gas is bubbled into the mixture for 1 hr.
  • the mixture is cooled to about 0 degrees C for the duration of the ammonia bubbling.
  • the reaction mixture is left stirring under a balloon of ammonia overnight at about 20-25 degrees C, and partitioned between saturated aqueous ammonium chloride and a water immiscible solvent, for example ethyl acetate .
  • the phases are separated and the aqueous phase is twice extracted with ethyl acetate.
  • the organic extracts are washed with saturated aqueous solutions of bicarbonate and saline and dried over anhydrous sodium or magnesium sulfate. Filtration of the drying agent and removal of solvents under reduced pressure yields the ester of the desired isophthalic acid or the isophthalic acid derivative acylating reagent (IX) .
  • Purification of the (methyl) ester can be carried by example via chromatography on silica gel with an isopropanol/chloroform eluting mixture.
  • the isophthalate ester or methylisophthalate ester of the primary amide is contacted with an aqueous alkaline solution such as lithium hydroxide in THF/methanol/water and stirred overnight at about 20-25 degrees C after which time the solvents are removed under reduced pressure and the solids are partitioned between water and a water immiscible solvent, for example ethyl acetate. If the formation of an emulsions hinders separation of the two phases, a small amount of saline solution is added to improve separation. The aqueous phase is separated and extracted with a water immiscible solvent, for example ethyl acetate.
  • a water immiscible solvent for example ethyl acetate.
  • the aqueous phase is then acidified with acid, preferably hydrochloric acid, to pH ⁇ 3.
  • acid preferably hydrochloric acid
  • the resulting mixture is extracted with ethyl acetate.
  • the combined organic ' extracts are dried over anhydrous sodium or magnesium sulfate.
  • the drying agent is removed by filtration and the organic solvent removed under reduced pressure to yield the product.
  • the amide isophthalic acid derivative is reacted with (VIII) to produce (X) .
  • the amine moiety be part of cyclic group, for example morpholinyl, piperazinyl, piperidinyl and pyrrolidinyl, etc the following method is preferably used.
  • An ester preferably the methyl ester of isophthalic acid or methyl 5-methyl-l, 3-isophthalate is dissolved in an anhydrous solvent, for example methylene chloride, and a small quantity of a dipolar aprotic solvent, for example DMF is added.
  • an anhydrous solvent for example methylene chloride
  • a dipolar aprotic solvent for example DMF
  • the mixture is cooled to about 0 degrees C and oxalyl chloride is added.
  • the mixture is stirred at about 0 degrees C for about 30 minutes to about two hours after which the solvents are removed under reduced pressure.
  • the crude acid chloride solid is left under vacuum overnight, and dissolved in dry methylene and cooled to about 0 degrees C prior to the addition of a cyclic amine and a tertiary amine base, for example N-methyl piperidine.
  • the reaction mixture is stirred at about 0 degrees C for about 1 to about 6 hrs before the solvents are removed under reduced pressure.
  • the residue is diluted with water and a water immiscible solvent, for example ethyl acetate, for example, and the phases are separated.
  • the aqueous phase is extracted with a water immiscible solvent, for example ethyl acetate, , and the combined organic extracts are washed with saturated aqueous bicarbonate and dried over anhydrous sodium or magnesium sulfate. Filtration of the drying agent and removal of solvents under reduced pressure yields the product cyclic amide.
  • the cyclic amide is contacted with an aqueous alkaline solution, for example lithium hydroxide in THF/methanol/water and stirred overnight at about 20-25 degrees C, after which time the solvents are removed under reduced pressure and the residue is partitioned between water and a water immiscible solvent, for example ethyl acetate.
  • aqueous phase is extracted with ethyl acetate. Removal of water from the aqueous phase under reduced pressure yields the target cyclic amide product (IX) .
  • R N _ 1 moiety in the target product is a carbocycle, for example but not limited to, cyclohexane
  • the starting reagent may be a suitably functionalized dimethyl isophthalate and the method one of those taught in the literature (Meyers, A.I., Org. Syn. , 1971, 51 , 103) one may reduce the six-membered ring with reducing agents such as rhodium (5%) on alumina in the presence of acetic acid and methanol under a hydrogen atmosphere to afford the corresponding dimethyl cyclohexane dicarboxylate .
  • CHART D sets forth an alternative process for production of the (S,R) -substituted amine (X) from the (S, R) -protected azide (XII) , which is produced from the corresponding epoxide
  • the (S,R)-free amine (XVI) is transformed to the corresponding (S, R) -substituted amine (X) by nitrogen alkylation with a compound of the formula R c -X 3 to give the corresponding (S,R) -substituted amine (X).
  • X 3 is an appropriate leaving group, such as but not limited to, -Cl, - Br, -I, -O-mesylate, -0-tosylate, O-triflate, etc.
  • X 3 may also be an aldehyde; the corresponding coupling with (XVI) via the well known reductive animation procedure gives the (S,R)- substituted amine (X) .
  • Carbocylic amide forming agents (IX) are also provided for by the invention.
  • R'-CH-C(R' ' ) (R' ' ' )-CH-X N -OH (IX) are readily prepared from known starting materials by methods disclosed in the literature and known to those skilled in the art, for example, J “ . Med. Chem . 1998, 41 , 1581, J “ . Org. Chem. 2000, 65, 1305. It is also understood that instead of the carboxylic acid, one may readily employ an acyl halide, where the halide is preferably choride, or a suitable group to produce a mixed anhydride; these methods are taught by CHART A. For additional guidance on the formation of carbocyles and preferably cyclopropanes, one may consult M.P. Doyle; M.A. McKervery; T. Ye in Modern Catalytic Methods for Organic Synthesis wi th Diazo Compounds From
  • CHART E discloses alternate processes for the transformation of the aniline (XVII) or acid ester (XVIII) to the corresponding acid (IX-XXIII) .
  • One process begins with the commercially available aniline (XVII) .
  • the aniline (XVII) is treated with a diazotizing reagent such as sodium or potassium nitrite in mineral acid, followed by a halogen source such as copper (II) halide or alkali metal halide, or by an organic diazotizing reagent such as an alkyl nitrite in a strong acid such as acetic acid or trifluoroacetic acid, followed by a halide source such as copper (II) halide or alkali metal halide to give the halo acid ester (XIX) .
  • a diazotizing reagent such as sodium or potassium nitrite in mineral acid
  • a halogen source such as copper (II) halide or alkali metal
  • the acid ester (XVIII) is treated with N- halosuccinimide and trifluoromethanesulfonic acid to give the halo acid ester (XIX) .
  • the halo acid ester (XIX) is then converted to the ester amide (XXI) using a primary or secondary amine of the formula H-NG ⁇ G where Gi and G 2 are the same or different or can be cyclized. Gi and G 2 become part of the substituted amine (X) and are included in the definition of R N .
  • R N includes R N _ ⁇ -X N - where the linker, -X N -, includes -CO- and R N _ ⁇ includes RN-aryi • RN-ryi is defined to include phenyl (- phenyl) optionally substituted with one or two amides: -CO-NR N _ 2 R N - 3 and -CO-R N _ 4 .
  • halo acid ester (XIX) is converted to the acid chloride halo ester (XX) by methods known to those skilled in the art.
  • acid halides may also be used.
  • the dihalo ester (XX) is treated with a primary or secondary amine of the formula H-NG ⁇ G 2 to give the ester amide (XXI) .
  • the ester amide (XXI) is treated with a primary or secondary amine of the formula H-NG ⁇ G 2 to give the ester amide (XXI) .
  • the diester (XXVI) is hydrolyzed using methods known to those skilled in the art to give the monoacid (XXVII) .
  • the monoacid (XXVII) is then converted to the diamide (XXII) using conditions such as for the conversion of the halo acid ester (XIX) to the ester amide (XXI) in CHART E.
  • CHART G discloses another route to prepare the ester amide
  • nitro compound (XXI) The reaction starts with commercially available nitro compound (XXVIII) which is condensed with an (AMINE) using coupling methods known to those skilled in the art to give the nitro amide (XXX) .
  • the nitro amide (XXX) can also be prepared by first treating the nitro compound (XXVIII) with reagents such as thionyl chloride, or DMF and oxalyl chloride, or other methods known to those skilled in the art to give the acyl chloride (XXIX) , which upon treatment with the (AMINE) gives the nitro amide (XXX) .
  • amide aniline (XXXI) Reduction of the nitro amide (XXX) using methods known to those skilled in the art (see, for example, Smith and March, Advanced Organic Chemistry, 5 th ed. ) gives amide aniline (XXXI) .
  • the amide aniline (XXXI) is then treated with diazotizing reagents such as sodium or potassium nitrite in mineral acid, followed by a halogen source such as copper (II) halide or alkali metal halide, or by an organic diazotizing reagent such as an alkyl nitrite in a strong acid such as acetic acid or trifluoroacetic acid, followed by a halide source such as copper (II) halide or alkali metal halide to give the ester amide (XXI) .
  • diazotizing reagents such as sodium or potassium nitrite in mineral acid
  • a halogen source such as copper (II) halide
  • CHART H discloses a process to prepare the diamide acid (IX-XXIII) from the ester amide (XXI) , where one of the amides is unsubstituted and is -CO-NH 2 .
  • This process starts from either the ester or the acid, for example the ester amide (XXI) is treated with copper (I) cyanide (CuCN) in N- methylpyrrolidinone or DMF, preferably N-methylpyrrolidinone, to give the nitrile (XXXII) .
  • the nitrile (XXXII) is converted to the primary amide (XXXIII) using urea-hydrogen peroxide complex (see Synth . Commun .
  • ester amide (XXI) is in the form of an ester
  • an additional hydrolysis step using lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide, or other hydrolysis methods known to those skilled in the art is used to convert the diamide ester (XXXIII) to the diamide acid (IX-XXIII) .
  • CHART I discloses an alternate synthetic route from the protected alcohol (VII) to the substituted amine (X) which uses a diprotected intermediate (XXXIV) wherein the nitrogen atom attached to the R c substitutent is protected.
  • XXXIV diprotected intermediate
  • the mono protected alcohol (VII) is reacted with a new protecting group to form the orthogonally protected (XXXIV) .
  • This is a common strategy employed in traditional peptide chemistry by those skilled in the art, see M. Bodansky, Principles of Peptide Chemistry.
PCT/US2002/036072 2001-11-08 2002-11-08 N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives WO2003040096A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CA002466284A CA2466284A1 (en) 2001-11-08 2002-11-08 N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives
EA200400648A EA200400648A1 (ru) 2001-11-08 2002-11-08 N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
MXPA04004428A MXPA04004428A (es) 2001-11-08 2002-11-08 Derivados de 2,3-diamino-2-hidroxipropano n,n`-sustituidos.
AU2002359376A AU2002359376B2 (en) 2001-11-08 2002-11-08 N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
APAP/P/2004/003049A AP2004003049A0 (en) 2001-11-08 2002-11-08 N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives.
JP2003542142A JP2005520791A (ja) 2001-11-08 2002-11-08 Ｎ，ｎ’−置換−１，３−ジアミノ−２−ヒドロキシプロパン誘導体
IL16188102A IL161881A0 (en) 2001-11-08 2002-11-08 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
NZ533107A NZ533107A (en) 2001-11-08 2002-11-08 N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
BR0214035-7A BR0214035A (pt) 2001-11-08 2002-11-08 Composto
EP02793909A EP1453789A2 (en) 2001-11-08 2002-11-08 N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives
ARP020104299A AR039555A1 (es) 2001-11-08 2002-11-08 Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano
YUP-505/04A RS50504A (en) 2001-11-08 2002-11-08 N,n'-substituted-1,3-diamino-2- hydroxypropane derivatives
IS7255A IS7255A (is) 2001-11-08 2004-05-07 Propan afleiður með mismunandi sethópa
IL161881A IL161881A (en) 2001-11-08 2004-05-09 N,n'-substituted-1,3-diamino-2- hydroxypropane derivatives
TNP2004000082A TNSN04082A1 (en) 2001-11-08 2004-05-10 N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives
NO20042359A NO20042359L (no) 2001-12-28 2004-06-07 N,N, substituerte-1,3-diamino-2-hydroksypropanderivater
HR20040518A HRP20040518A2 (en) 2001-11-08 2004-06-07 N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33712201P 2001-11-08 2001-11-08
US60/337,122 2001-11-08
US34408601P 2001-12-28 2001-12-28
US60/344,086 2001-12-28
US34563502P 2002-01-03 2002-01-03
US60/345,635 2002-01-03

Publications (2)

Publication Number Publication Date
WO2003040096A2 true WO2003040096A2 (en) 2003-05-15
WO2003040096A3 WO2003040096A3 (en) 2004-05-06

Family

ID=27407177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036072 WO2003040096A2 (en) 2001-11-08 2002-11-08 N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives

Country Status (23)

Country Link
US (2) US7176242B2 (US07727997-20100601-C00067.png)
EP (1) EP1453789A2 (US07727997-20100601-C00067.png)
JP (1) JP2005520791A (US07727997-20100601-C00067.png)
KR (1) KR20050044407A (US07727997-20100601-C00067.png)
AP (1) AP2004003049A0 (US07727997-20100601-C00067.png)
AR (1) AR039555A1 (US07727997-20100601-C00067.png)
AU (1) AU2002359376B2 (US07727997-20100601-C00067.png)
BR (1) BR0214035A (US07727997-20100601-C00067.png)
CA (1) CA2466284A1 (US07727997-20100601-C00067.png)
CO (1) CO5640093A2 (US07727997-20100601-C00067.png)
EA (1) EA200400648A1 (US07727997-20100601-C00067.png)
EC (1) ECSP045100A (US07727997-20100601-C00067.png)
GE (1) GEP20074171B (US07727997-20100601-C00067.png)
HR (1) HRP20040518A2 (US07727997-20100601-C00067.png)
IL (2) IL161881A0 (US07727997-20100601-C00067.png)
IS (1) IS7255A (US07727997-20100601-C00067.png)
MX (1) MXPA04004428A (US07727997-20100601-C00067.png)
NZ (1) NZ533107A (US07727997-20100601-C00067.png)
OA (1) OA12846A (US07727997-20100601-C00067.png)
RS (1) RS50504A (US07727997-20100601-C00067.png)
TN (1) TNSN04082A1 (US07727997-20100601-C00067.png)
TW (1) TW200304808A (US07727997-20100601-C00067.png)
WO (1) WO2003040096A2 (US07727997-20100601-C00067.png)

Cited By (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000821A1 (en) * 2002-06-20 2003-12-31 Pharmacia & Upjohn Company Process for preparing 5-(1, 3-oxazol-2-yl) benzoic acid derivatives
WO2004007461A1 (en) * 2002-07-16 2004-01-22 Prana Biotechnology Limited 8-hydroxy quinoline derivatives
WO2004014843A1 (ja) * 2002-08-09 2004-02-19 Takeda Chemical Industries, Ltd. 置換アミノ化合物およびその用途
WO2004037814A1 (en) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
WO2004050609A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
WO2004063173A1 (en) * 2003-01-10 2004-07-29 Dipharma S.P.A. A process for the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid and the intermediates thereof
WO2004078723A1 (ja) * 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
WO2004094384A2 (en) * 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease
WO2005030709A1 (en) * 2003-10-01 2005-04-07 Lg Life Sciences Ltd. Novel sulfone amide derivatives capable of inhibiting bace
EP1521577A1 (en) * 2002-06-13 2005-04-13 QLT, Inc. Methods of using isothiazole derivatives to treat cancer or inflammation
WO2005044830A1 (en) * 2003-11-11 2005-05-19 F. Hoffmann-La Roche Ag Phosphinic acids derivatives, beta-secretase inhibitors for the treatment of alzheimer’s disease
WO2005058915A1 (en) * 2003-12-12 2005-06-30 Glaxo Group Limited Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease
WO2005070407A1 (en) * 2004-01-21 2005-08-04 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
WO2005087714A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
WO2005087751A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
WO2005108391A1 (en) 2004-04-22 2005-11-17 Eli Lilly And Company Amides as bace inhibitors
WO2005113525A1 (en) * 2004-05-21 2005-12-01 Glaxo Group Limited N, n’-substituted-1,3-diamino-2-oxopropane derivatives, their pharmaceutical compositions and use
WO2006010095A2 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2006010094A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
WO2006040148A1 (en) * 2004-10-13 2006-04-20 Glaxo Group Limited Tricyclic indole derivatives for use in the treatment of alzheimer’s disease
WO2006043710A1 (ja) * 2004-10-19 2006-04-27 Reverse Proteomics Research Institute Co., Ltd. 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
EP1682105A2 (en) * 2003-11-13 2006-07-26 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
WO2006085216A1 (en) * 2005-02-14 2006-08-17 Pfizer Products Inc. Substituted hydroxyethylamines
WO2006098962A1 (en) * 2005-03-09 2006-09-21 Schering Corporation Compounds for inhibiting ksp kinesin activity
WO2007017511A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Verbindungen zur behandlung der alzheimer erkrankung
WO2007017510A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Isophthalsäurediamide zur behandlung der alzheimer erkrankung
WO2007061930A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
WO2007062007A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
JP2007517781A (ja) * 2003-12-19 2007-07-05 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病治療用のフェニルアミドおよびピリジルアミド系β−セクレターゼ阻害薬
EP1565443A4 (en) * 2002-09-10 2007-07-18 Elan Pharm Inc ACETYL 2-HYDROXY-1,3-DIAMINOALKANE
US7253198B2 (en) 2002-12-05 2007-08-07 Glaxo Group Limited Hydroxyethylamine derivatives for the treatment of Alzheimer's disease
WO2007097276A1 (ja) 2006-02-20 2007-08-30 Astellas Pharma Inc. ピロール誘導体またはその塩
WO2007110727A2 (en) * 2006-03-27 2007-10-04 Pfizer Products Inc. Amide stabilized hydroxyethylamines
JP2007528402A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
JP2008502684A (ja) * 2004-06-15 2008-01-31 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病を治療するためのベータ−セクレターゼ阻害剤として有用なピロリジン−３−イル化合物
JP2008513386A (ja) * 2004-09-20 2008-05-01 ４エスシー アーゲー 新規な複素環式ＮＦ−κＢ阻害剤
JP2008535863A (ja) * 2005-04-08 2008-09-04 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害する化合物およびその使用方法
US7425436B2 (en) 2004-07-30 2008-09-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
US7429472B2 (en) 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
FR2918984A1 (fr) * 2007-07-16 2009-01-23 Sanofi Aventis Sa Derives de pyrazole 3,5-carboxylates,leur preparation et leur application en therapeutique
FR2919286A1 (fr) * 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
FR2919285A1 (fr) * 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application etn therapeutique.
US7544703B2 (en) 2004-02-17 2009-06-09 Santen Pharmaceutical Co., Ltd. Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
US7589094B2 (en) * 2001-07-11 2009-09-15 Elan Pharmaceuticals, Inc. N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
EP2116526A1 (en) * 2006-12-29 2009-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Derivates of substituted tartaric aicd and usage for preparating beta secretase inhibitors
EP2177503A1 (en) * 2004-02-20 2010-04-21 UCL Business PLC Modulators of cannabinoid receptors
WO2010107384A1 (en) * 2009-03-19 2010-09-23 Medivir Ab Aspartyl protease inhibitors
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
US7825122B2 (en) 2005-12-14 2010-11-02 Amgen Inc. Diaza heterocyclic sulfonamide derivatives and their uses
US7906556B2 (en) 2005-10-12 2011-03-15 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2010102212A3 (en) * 2009-03-06 2011-03-31 The University Of North Carolina At Chapel Hill Neurotrophin mimetics and uses thereof
US7932250B2 (en) 2004-07-01 2011-04-26 Daiichi Sankyo Company, Limited Thienopyrazole derivative having PDE7 inhibitory activity
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063272A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011090911A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
USRE42931E1 (en) 2003-01-31 2011-11-15 Promega Corporation Covalent tethering of functional groups to proteins
CN101781268B (zh) * 2010-02-25 2012-05-30 中国人民解放军军事医学科学院毒物药物研究所 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途
US8207168B2 (en) 2006-07-25 2012-06-26 Cephalon, Inc. Pyridazinone derivatives
US8299267B2 (en) 2007-09-24 2012-10-30 Comentis, Inc. (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
JP2013032373A (ja) * 2005-04-15 2013-02-14 Univ Of North Carolina At Chapel Hill ニューロトロフィン類似体を用いた細胞生存促進法
US8420367B2 (en) 2006-10-30 2013-04-16 Promega Corporation Polynucleotides encoding mutant hydrolase proteins with enhanced kinetics and functional expression
US8765746B2 (en) 2010-10-13 2014-07-01 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8796268B2 (en) 2010-08-11 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9029358B2 (en) 2005-10-25 2015-05-12 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9212149B2 (en) 2004-04-30 2015-12-15 Takeda Pharmaceutical Company Limited Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors
WO2017066742A1 (en) * 2015-10-16 2017-04-20 Jortan Pharmaceuticals Inc. Bace-2 inhibitory compounds and related methods of use
US9650371B2 (en) 2008-06-13 2017-05-16 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US9656974B2 (en) 2009-12-11 2017-05-23 Shionogi & Co., Ltd. Oxazine derivatives
EP3081556A4 (en) * 2013-12-10 2017-06-07 Japan Science and Technology Agency Amide compound and pharmaceutical comprising same
US9758513B2 (en) 2012-10-24 2017-09-12 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
US9833420B2 (en) 2003-02-27 2017-12-05 JoAnne McLaurin Methods of preventing, treating, and diagnosing disorders of protein aggregation
US9873678B2 (en) 2014-03-18 2018-01-23 Astrazeneca Ab Chemical compounds
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CN110407763A (zh) * 2019-08-08 2019-11-05 苏州汉德创宏生化科技有限公司 一种4-（噁唑-2-基）苯甲酸的合成方法
US10532988B2 (en) 2009-11-12 2020-01-14 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2023139581A1 (en) * 2022-01-18 2023-07-27 Bsense Bio Therapeutics Ltd. Modulators of a potassium channel and of trpv1 channel and uses thereof

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410972A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
DE10034673C1 (de) * 2000-07-17 2002-04-25 Medac Klinische Spezialpraep Dermales Applikationssystem für Aminolävulinsäure und seine Verwendung
AR037460A1 (es) * 2001-11-30 2004-11-10 Smithkline Beecham Plc Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion
EP1453788A1 (en) * 2001-12-06 2004-09-08 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
DE10202487A1 (de) * 2002-01-23 2003-07-31 Photonamic Gmbh & Co Kg Dermales Applikationssystem für Aminolävulinsäure-Derivate
EP1515944A1 (en) * 2002-06-17 2005-03-23 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7294642B2 (en) * 2002-09-06 2007-11-13 Elan Pharmaceuticals, Inc. 1,3-Diamino-2-hydroxypropane pro-drug derivatives
EP1562897B1 (en) * 2002-11-12 2009-09-16 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
PE20050420A1 (es) * 2003-04-21 2005-06-13 Elan Pharm Inc Fenacilo 2-hidroxi-3-diaminoalcanos
CA2543756A1 (en) * 2003-10-30 2005-05-12 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer's disease
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2580238A1 (en) * 2004-09-17 2006-03-30 Comentis, Inc. Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
JP5067968B2 (ja) * 2004-10-07 2012-11-07 ビテ ファーマシューティカルズ， インコーポレイテッド ジアミノアルカンアスパラギン酸プロテアーゼ阻害剤
CN101142194B (zh) * 2005-03-14 2012-10-10 顶点制药有限责任公司 吲哚衍生物，组合物及用作β-分泌酶抑制剂的方法
WO2007016609A2 (en) * 2005-08-02 2007-02-08 Smithkline Beecham Corporation Method for the synthesis of quinoliνe derivatives
TWI411607B (zh) * 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
TWI423819B (zh) * 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
JP2009531443A (ja) * 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
US7872028B2 (en) * 2006-04-05 2011-01-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
US7563797B2 (en) * 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
ATE520690T1 (de) * 2006-09-18 2011-09-15 Vitae Pharmaceuticals Inc Piperidinderivate als renin-inhibitoren
US8501933B2 (en) 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
ES2367455T3 (es) * 2006-11-09 2011-11-03 F. Hoffmann-La Roche Ag Arilamidas sustituidas por tiazol u oxazol.
JP5383484B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 環式基で置換されたアミノジヒドロチアジン誘導体
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
WO2008137168A2 (en) * 2007-05-07 2008-11-13 True Charles W Collapsible, stackable, semi-rigid universal tank for hazardous and non-hazardous goods
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US20100160424A1 (en) * 2007-06-20 2010-06-24 Baldwin John J Renin inhibitors
WO2009096996A1 (en) * 2007-06-20 2009-08-06 Smithkline Beecham Corporation Renin inhibitors
KR20100051668A (ko) * 2007-07-26 2010-05-17 코멘티스, 인코포레이티드 베타-세크레타제 활성을 억제하는 이소프탈아미드 유도체
WO2009038412A2 (en) * 2007-09-21 2009-03-26 Lg Life Sciences, Ltd. Beta-secretase inhibiting compounds
BRPI0821266B8 (pt) * 2007-12-17 2023-02-07 Hoffmann La Roche Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
EP2570407B1 (en) * 2007-12-17 2014-08-13 F. Hoffmann-La Roche AG Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists
PT2234976E (pt) * 2007-12-17 2013-07-11 Hoffmann La Roche Novas arilamidas substituídas por pirazol
WO2009077365A1 (en) * 2007-12-17 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazole-substituted arylamides
US7960397B2 (en) * 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
JP2011525488A (ja) * 2008-06-20 2011-09-22 ヴァイティー ファーマシューティカルズ，インコーポレイテッド レニン阻害剤およびその使用方法
CN102088850A (zh) * 2008-06-26 2011-06-08 生命医药公司 甲基2-((r)-(3-氯苯基)((r)-1-((s)-2-(甲氨基)-3((r)-四氢-2h-吡喃-3-基)丙基氨甲酰基)哌啶-3-基)甲氧基)氨基甲酸乙酯的盐
CA2736130C (en) * 2008-09-11 2014-01-14 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
JP2012505241A (ja) * 2008-10-10 2012-03-01 パーデュー・リサーチ・ファウンデーション アルツハイマー病の治療用組成物
JP2012509352A (ja) * 2008-11-20 2012-04-19 パーデュー・リサーチ・ファウンデーション Ｂａｃｅ１のキナゾリン阻害剤および使用方法
PE20150939A1 (es) 2008-12-03 2015-07-19 Presidio Pharmaceuticals Inc Inhibidores de la proteina no estructural 5a del virus de la hepatitis c
US8859590B2 (en) 2008-12-05 2014-10-14 Purdue Research Foundation Inhibitors of BACE1 and methods for treating Alzheimer's disease
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
AR077692A1 (es) * 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
US8497264B2 (en) 2010-03-15 2013-07-30 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US8883782B2 (en) 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2012147763A1 (ja) 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014100734A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2935243B1 (en) 2012-12-21 2018-03-14 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
HUE040323T2 (hu) 2012-12-21 2019-02-28 Epizyme Inc PRMT5-inhibitorok és alkalmazásaik
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
BR112015020650A2 (pt) * 2013-02-27 2017-07-18 Epitherapeutics Aps inibidores de histona demetilases
JP2017530940A (ja) 2014-08-04 2017-10-19 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
US20230391732A1 (en) 2020-07-31 2023-12-07 Shenzhen Olive Biopharmaceuticals Co., Ltd Multi-efficacy pyrazine compound, preparation method and use thereof
CN112876460B (zh) * 2021-02-05 2022-05-31 山西大学 7-二乙胺基-3-乙酰基香豆素衍生物及其合成方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652009A1 (en) * 1993-08-09 1995-05-10 Eli Lilly And Company Identification and use of protease inhibitors
WO1998033795A1 (en) * 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
WO2002002505A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002002520A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002002512A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002014264A2 (en) * 2000-08-11 2002-02-21 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1599907A (en) * 1977-04-26 1981-10-07 Glaxo Lab Ltd Isoindolines
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0647268B1 (en) * 1990-06-15 2004-03-03 Scios Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5912410A (en) * 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
WO1992008701A1 (en) * 1990-11-19 1992-05-29 Monsanto Company Retroviral protease inhibitors
DE69233774D1 (de) * 1991-01-21 2009-12-10 Elan Pharm Inc Prüfung und Modell für Alzheimers-Krankheit
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FI95420C (fi) * 1991-11-13 1997-05-14 Heikki Korkala Älykäs lamppu tai lampun älykäs liitäntäkanta
WO1993014200A1 (en) * 1992-01-07 1993-07-22 Tsi Corporation Transgenic animal models for alzheimer's disease
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5783701A (en) * 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
ATE198622T1 (de) * 1993-10-27 2001-01-15 Elan Pharm Inc Transgene tiere, die app allele mit der schwedischen mutation beherbergen
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5942400A (en) * 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
WO1998022597A2 (en) 1996-11-20 1998-05-28 Oklahoma Medical Research Foundation Cloning and characterization of napsin, an aspartic protease
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
ES2318902T3 (es) 1998-09-24 2009-05-01 PHARMACIA & UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
WO2000047618A2 (en) 1999-02-10 2000-08-17 Elan Pharmaceuticals, Inc. HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
JP2003523944A (ja) 1999-08-09 2003-08-12 ヴァンダービルト ユニヴァースティ Ｐ−糖タンパク質修飾物質を用いる抗ウィルス療法
PT1224297E (pt) 1999-09-23 2009-08-17 Pharmacia & Upjohn Co Llc Secretase da doença de alzheimer, seus substratos app e suas utilizações
DE10008968A1 (de) 2000-02-25 2001-09-27 Siemens Ag Bestückvorrichtung mit einer beweglichen Zuführeinrichtung für elektrische Bauteile

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652009A1 (en) * 1993-08-09 1995-05-10 Eli Lilly And Company Identification and use of protease inhibitors
WO1998033795A1 (en) * 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
WO2002002505A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002002518A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002002520A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002002512A2 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
WO2002014264A2 (en) * 2000-08-11 2002-02-21 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEVALLIER N ET AL: "CATHEPSIN D DISPLAYS IN VITRO BETA-SECRETASE-LIKE SPECIFICITY" BRAIN RESEARCH, AMSTERDAM, NL, vol. 750, no. 1/2, 1997, pages 11-19, XP000921314 ISSN: 0006-8993 *

Cited By (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589094B2 (en) * 2001-07-11 2009-09-15 Elan Pharmaceuticals, Inc. N- (3-amino-2-hydroxy-propyl) substituted alkylamide compounds
EP1521577A1 (en) * 2002-06-13 2005-04-13 QLT, Inc. Methods of using isothiazole derivatives to treat cancer or inflammation
WO2004000821A1 (en) * 2002-06-20 2003-12-31 Pharmacia & Upjohn Company Process for preparing 5-(1, 3-oxazol-2-yl) benzoic acid derivatives
US7115747B2 (en) 2002-06-20 2006-10-03 Pharmacia & Upjohn Company Process for preparing oxazole intermediates
EA008389B1 (ru) * 2002-06-20 2007-04-27 Фармация Энд Апджон Компани Ллс Способ получения производных 5-(1,3-оксазол-2-ил)бензойной кислоты
CN1324017C (zh) * 2002-06-20 2007-07-04 法玛西和厄普约翰有限责任公司 5－(1,3－噁唑－2－基)苯甲酸衍生物的制备方法
US9302993B2 (en) 2002-07-16 2016-04-05 Prana Biotechnology Limited 8-hydroxy quinoline derivatives
US9169211B2 (en) 2002-07-16 2015-10-27 Prana Biotechnology Limited 8-hydroxy quinoline derivatives
US7619091B2 (en) 2002-07-16 2009-11-17 Prana Biotechnology Limited 8-hydroxy quinoline derivatives
US8975278B2 (en) 2002-07-16 2015-03-10 Prana Biotechnology Limited 8-hydroxy quinoline derivatives
WO2004007461A1 (en) * 2002-07-16 2004-01-22 Prana Biotechnology Limited 8-hydroxy quinoline derivatives
WO2004014843A1 (ja) * 2002-08-09 2004-02-19 Takeda Chemical Industries, Ltd. 置換アミノ化合物およびその用途
EP1565443A4 (en) * 2002-09-10 2007-07-18 Elan Pharm Inc ACETYL 2-HYDROXY-1,3-DIAMINOALKANE
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7842712B2 (en) 2002-10-25 2010-11-30 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
WO2004037814A1 (en) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7351738B2 (en) * 2002-11-27 2008-04-01 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
WO2004050609A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
US7253198B2 (en) 2002-12-05 2007-08-07 Glaxo Group Limited Hydroxyethylamine derivatives for the treatment of Alzheimer's disease
US7291742B2 (en) 2003-01-10 2007-11-06 Dipharma S.P.A. Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof
WO2004063173A1 (en) * 2003-01-10 2004-07-29 Dipharma S.P.A. A process for the preparation of benzo[d]isoxazol-3-yl-methanesulfonic acid and the intermediates thereof
US7888086B2 (en) 2003-01-31 2011-02-15 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
US9540402B2 (en) 2003-01-31 2017-01-10 Promega Corporation Covalent tethering of functional groups to proteins
US8202700B2 (en) 2003-01-31 2012-06-19 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
US10604745B2 (en) 2003-01-31 2020-03-31 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
US11028424B2 (en) 2003-01-31 2021-06-08 Promega Corporation Covalent tethering of functional groups to proteins
US8921620B2 (en) 2003-01-31 2014-12-30 Promega Corporation Compositions comprising a dehalogenase substrate and a contrast agent and methods of use
USRE42931E1 (en) 2003-01-31 2011-11-15 Promega Corporation Covalent tethering of functional groups to proteins
US7429472B2 (en) 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
US8257939B2 (en) 2003-01-31 2012-09-04 Promega Corporation Compositions comprising a dehalogenase substrate and a fluorescent label and methods of use
US8779221B2 (en) 2003-01-31 2014-07-15 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
US8895787B2 (en) 2003-01-31 2014-11-25 Promega Corporation Compositions comprising a dehalogenase substrate and a radionuclide and methods of use
US10240184B2 (en) 2003-01-31 2019-03-26 Promega Corporation Covalent tethering of functional groups to proteins
US9833420B2 (en) 2003-02-27 2017-12-05 JoAnne McLaurin Methods of preventing, treating, and diagnosing disorders of protein aggregation
US8518973B2 (en) 2003-03-07 2013-08-27 Santen Pharmaceutical Co., Ltd. Compounds having 4-pyridylalkylthio group as a substituent
EP2527326A1 (en) * 2003-03-07 2012-11-28 Santen Pharmaceutical Co., Ltd Novel compounds having 4-pyridylalkylthio group as substituent
US7534802B2 (en) 2003-03-07 2009-05-19 Santen Pharmaceutical Co., Ltd. Compounds having 4-pyridylalkylthio group as substituent
US8207194B2 (en) 2003-03-07 2012-06-26 Santen Pharmaceutical Co., Ltd. Compounds having a 4-pyridylalkylthio group as a substituent
WO2004078723A1 (ja) * 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
WO2004094384A2 (en) * 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease
US7223774B2 (en) 2003-04-21 2007-05-29 Elan Pharmaceuticals, Inc. Benzamide 2-hydroxy-3-diaminoalkanes
WO2004094384A3 (en) * 2003-04-21 2005-02-03 Elan Pharm Inc (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease
WO2005030709A1 (en) * 2003-10-01 2005-04-07 Lg Life Sciences Ltd. Novel sulfone amide derivatives capable of inhibiting bace
KR100793095B1 (ko) 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
WO2005044830A1 (en) * 2003-11-11 2005-05-19 F. Hoffmann-La Roche Ag Phosphinic acids derivatives, beta-secretase inhibitors for the treatment of alzheimer’s disease
KR100782618B1 (ko) * 2003-11-11 2007-12-06 에프. 호프만-라 로슈 아게 알쯔하이머 병의 치료를 위한 포스핀산 유도체,베타-세크레타제 억제제
US7345082B2 (en) 2003-11-11 2008-03-18 Hoffmann-La Roche Inc. Phosphinic acids
EP1682105A2 (en) * 2003-11-13 2006-07-26 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
EP1682105A4 (en) * 2003-11-13 2008-12-24 Bristol Myers Squibb Co N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
WO2005058915A1 (en) * 2003-12-12 2005-06-30 Glaxo Group Limited Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease
JP2007517781A (ja) * 2003-12-19 2007-07-05 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病治療用のフェニルアミドおよびピリジルアミド系β−セクレターゼ阻害薬
WO2005070407A1 (en) * 2004-01-21 2005-08-04 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
US7544703B2 (en) 2004-02-17 2009-06-09 Santen Pharmaceutical Co., Ltd. Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
EP2177503A1 (en) * 2004-02-20 2010-04-21 UCL Business PLC Modulators of cannabinoid receptors
AU2005214146B2 (en) * 2004-02-20 2012-02-23 Canbex Therapeutics Limited Modulators of cannabinoid receptors
US9120723B2 (en) 2004-02-20 2015-09-01 Canbex Therapeutics Limited Modulator
AU2005214146C1 (en) * 2004-02-20 2012-09-20 Canbex Therapeutics Limited Modulators of cannabinoid receptors
WO2005087751A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007528400A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
JP2007528402A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US7858642B2 (en) 2004-03-09 2010-12-28 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
WO2005087751A3 (en) * 2004-03-09 2005-12-15 Elan Pharm Inc Substituted hydroxyethylamine aspartyl protease inhibitors
WO2005087714A3 (en) * 2004-03-09 2005-12-15 Elan Pharm Inc Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
WO2005087714A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
WO2005108391A1 (en) 2004-04-22 2005-11-17 Eli Lilly And Company Amides as bace inhibitors
US9475822B2 (en) 2004-04-30 2016-10-25 Takeda Pharmaceutical Company Limited Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors
US9212149B2 (en) 2004-04-30 2015-12-15 Takeda Pharmaceutical Company Limited Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors
WO2005113525A1 (en) * 2004-05-21 2005-12-01 Glaxo Group Limited N, n’-substituted-1,3-diamino-2-oxopropane derivatives, their pharmaceutical compositions and use
JP2008502684A (ja) * 2004-06-15 2008-01-31 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病を治療するためのベータ−セクレターゼ阻害剤として有用なピロリジン−３−イル化合物
US8901315B2 (en) 2004-07-01 2014-12-02 Daiichi Sankyo Company, Limited Thienopyrazole derivative having PDE7 inhibitory activity
US7932250B2 (en) 2004-07-01 2011-04-26 Daiichi Sankyo Company, Limited Thienopyrazole derivative having PDE7 inhibitory activity
EP2433943A1 (en) 2004-07-01 2012-03-28 Daiichi Sankyo Company, Limited Thienopyrazole derivatives having PDE7 inhibitory activity
JP2008505929A (ja) * 2004-07-09 2008-02-28 エラン ファーマシューティカルズ，インコーポレイテッド オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
WO2006010095A3 (en) * 2004-07-09 2006-06-08 Elan Pharm Inc Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US7385085B2 (en) 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2006010095A2 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
WO2006010094A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
US7935803B2 (en) 2004-07-30 2011-05-03 Promega Corporation Polynucleotides encoding proteins for covalent tethering to functional groups and substrates
US8168405B2 (en) 2004-07-30 2012-05-01 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
US8466269B2 (en) 2004-07-30 2013-06-18 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
US10101332B2 (en) 2004-07-30 2018-10-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
US7425436B2 (en) 2004-07-30 2008-09-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
US8742086B2 (en) 2004-07-30 2014-06-03 Promega Corporation Polynucleotide encoding a mutant dehalogenase to allow tethering to functional groups and substrates
US9416353B2 (en) 2004-07-30 2016-08-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
JP2008513386A (ja) * 2004-09-20 2008-05-01 ４エスシー アーゲー 新規な複素環式ＮＦ−κＢ阻害剤
WO2006040148A1 (en) * 2004-10-13 2006-04-20 Glaxo Group Limited Tricyclic indole derivatives for use in the treatment of alzheimer’s disease
WO2006043710A1 (ja) * 2004-10-19 2006-04-27 Reverse Proteomics Research Institute Co., Ltd. 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
US8178077B2 (en) 2004-10-19 2012-05-15 Reverse Proteomics Research Institute Co., Ltd. Drug development target protein and target gene, and method of screening
WO2006085216A1 (en) * 2005-02-14 2006-08-17 Pfizer Products Inc. Substituted hydroxyethylamines
WO2006098962A1 (en) * 2005-03-09 2006-09-21 Schering Corporation Compounds for inhibiting ksp kinesin activity
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
US7504420B2 (en) 2005-04-08 2009-03-17 Comentis, Inc. Compounds which inhibit beta-secretase activity and methods of use
JP2008535863A (ja) * 2005-04-08 2008-09-04 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害する化合物およびその使用方法
US8916556B2 (en) 2005-04-15 2014-12-23 The University Of North Carolina At Chapel Hill Pharmaceutical formulations comprising neurotrophin mimetics
EP2586445A1 (en) * 2005-04-15 2013-05-01 University Of North Carolina At Chapel Hill Methods of facilitating cell survival using neurotrophin mimetics
JP2013032373A (ja) * 2005-04-15 2013-02-14 Univ Of North Carolina At Chapel Hill ニューロトロフィン類似体を用いた細胞生存促進法
WO2007017511A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Verbindungen zur behandlung der alzheimer erkrankung
WO2007017510A2 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Isophthalsäurediamide zur behandlung der alzheimer erkrankung
WO2007017511A3 (de) * 2005-08-11 2007-04-26 Boehringer Ingelheim Int Verbindungen zur behandlung der alzheimer erkrankung
WO2007017510A3 (de) * 2005-08-11 2008-02-28 Boehringer Ingelheim Int Isophthalsäurediamide zur behandlung der alzheimer erkrankung
US7906556B2 (en) 2005-10-12 2011-03-15 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US9029358B2 (en) 2005-10-25 2015-05-12 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
WO2007061930A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
WO2007062007A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US7825122B2 (en) 2005-12-14 2010-11-02 Amgen Inc. Diaza heterocyclic sulfonamide derivatives and their uses
WO2007097276A1 (ja) 2006-02-20 2007-08-30 Astellas Pharma Inc. ピロール誘導体またはその塩
US8222274B2 (en) 2006-02-20 2012-07-17 Astellas Pharma Inc. Pyrrole derivative or salt thereof
WO2007110727A2 (en) * 2006-03-27 2007-10-04 Pfizer Products Inc. Amide stabilized hydroxyethylamines
WO2007110727A3 (en) * 2006-03-27 2007-12-06 Pfizer Prod Inc Amide stabilized hydroxyethylamines
US8247414B2 (en) 2006-07-25 2012-08-21 Cephalon, Inc. Pyridizinone derivatives and the use thereof as H3 inhibitors
US8673916B2 (en) 2006-07-25 2014-03-18 Cephalon, Inc. Methods of treating disorders mediated by histamine H3 receptors using pyridazinone derivatives
US8207168B2 (en) 2006-07-25 2012-06-26 Cephalon, Inc. Pyridazinone derivatives
US8586588B2 (en) 2006-07-25 2013-11-19 Cephalon, Inc. Aryl pyridazinone derivatives and their use as H3 receptor ligands
US8748148B2 (en) 2006-10-30 2014-06-10 Promega Corporation Polynucleotides encoding mutant hydrolase proteins with enhanced kinetics and functional expression
US8420367B2 (en) 2006-10-30 2013-04-16 Promega Corporation Polynucleotides encoding mutant hydrolase proteins with enhanced kinetics and functional expression
US9593316B2 (en) 2006-10-30 2017-03-14 Promega Corporation Polynucleotides encoding mutant hydrolase proteins with enhanced kinetics and functional expression
US9873866B2 (en) 2006-10-30 2018-01-23 Promega Corporation Mutant dehalogenase proteins
US10246690B2 (en) 2006-10-30 2019-04-02 Promega Corporation Mutant hydrolase proteins with enhanced kinetics and functional expression
US8268884B2 (en) 2006-12-29 2012-09-18 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Derivatives of substituted tartaric acid and usage for preparing beta-secretase inhibitors
EP2116526A1 (en) * 2006-12-29 2009-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Derivates of substituted tartaric aicd and usage for preparating beta secretase inhibitors
EP2116526A4 (en) * 2006-12-29 2012-02-29 Inst Pharm & Toxicology Amms SUBSTITUTED TARTARIC ACID DERIVATIVES AND USES THEREOF FOR PREPARING BETA-SECRETASE INHIBITORS
WO2008147544A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
WO2009027601A2 (fr) 2007-07-16 2009-03-05 Sanofi-Aventis Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique
US9102628B2 (en) 2007-07-16 2015-08-11 Sanofi Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics
FR2918984A1 (fr) * 2007-07-16 2009-01-23 Sanofi Aventis Sa Derives de pyrazole 3,5-carboxylates,leur preparation et leur application en therapeutique
WO2009027601A3 (fr) * 2007-07-16 2009-05-14 Sanofi Aventis Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique
AU2008306763B2 (en) * 2007-07-27 2013-08-29 Sanofi-Aventis 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
US8372864B2 (en) 2007-07-27 2013-02-12 Sanofi 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
FR2919285A1 (fr) * 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application etn therapeutique.
FR2919286A1 (fr) * 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
WO2009044018A2 (fr) * 2007-07-27 2009-04-09 Sanofi-Aventis Dérivés de 1-0x0-1,2-dihydroisoquinoleine-5-carboxamides et de 4-oxo-3,4-dihydroquinazoline-8-carboxamides, leur préparation et leur application en thérapeutique
WO2009044019A2 (fr) * 2007-07-27 2009-04-09 Sanofi-Aventis Dérivés de 1-oxo-isoindoline-4-carboxamides et de 1-oxo-1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur préparation et leur application en thérapeutique
US8030320B2 (en) 2007-07-27 2011-10-04 Sanofi-Aventis Derivatives of 1-OXO-1,2-dihydroisoquinoline-5-carboxamides and of 4-OXO-3,4-dihydroquinazoline-8-carboxamides, preparation thereof and application thereof in therapeutics
WO2009044019A3 (fr) * 2007-07-27 2009-06-18 Sanofi Aventis Dérivés de 1-oxo-isoindoline-4-carboxamides et de 1-oxo-1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur préparation et leur application en thérapeutique
WO2009044018A3 (fr) * 2007-07-27 2009-06-18 Sanofi Aventis Dérivés de 1-0x0-1,2-dihydroisoquinoleine-5-carboxamides et de 4-oxo-3,4-dihydroquinazoline-8-carboxamides, leur préparation et leur application en thérapeutique
US8299267B2 (en) 2007-09-24 2012-10-30 Comentis, Inc. (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
US7951838B2 (en) 2007-11-14 2011-05-31 Amgen Inc. Substituted spirocyclic chromanamine compounds as Beta-Secretase modulators and methods of use
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
US9650371B2 (en) 2008-06-13 2017-05-16 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
WO2010102212A3 (en) * 2009-03-06 2011-03-31 The University Of North Carolina At Chapel Hill Neurotrophin mimetics and uses thereof
WO2010107384A1 (en) * 2009-03-19 2010-09-23 Medivir Ab Aspartyl protease inhibitors
US11225467B2 (en) 2009-11-12 2022-01-18 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10532988B2 (en) 2009-11-12 2020-01-14 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063272A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US9656974B2 (en) 2009-12-11 2017-05-23 Shionogi & Co., Ltd. Oxazine derivatives
WO2011090911A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CN101781268B (zh) * 2010-02-25 2012-05-30 中国人民解放军军事医学科学院毒物药物研究所 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8796271B2 (en) 2010-08-11 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8796268B2 (en) 2010-08-11 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8765746B2 (en) 2010-10-13 2014-07-01 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9758513B2 (en) 2012-10-24 2017-09-12 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
EP3081556A4 (en) * 2013-12-10 2017-06-07 Japan Science and Technology Agency Amide compound and pharmaceutical comprising same
US9796677B2 (en) 2013-12-10 2017-10-24 Japan Science And Technology Agency Amide compound and pharmaceutical comprising same
US9873678B2 (en) 2014-03-18 2018-01-23 Astrazeneca Ab Chemical compounds
US10954211B2 (en) 2014-03-18 2021-03-23 Astrazeneca Ab Chemical compounds
US10336725B2 (en) 2014-03-18 2019-07-02 Astrazeneca Ab Chemical compounds
WO2017066742A1 (en) * 2015-10-16 2017-04-20 Jortan Pharmaceuticals Inc. Bace-2 inhibitory compounds and related methods of use
CN110407763A (zh) * 2019-08-08 2019-11-05 苏州汉德创宏生化科技有限公司 一种4-（噁唑-2-基）苯甲酸的合成方法
CN110407763B (zh) * 2019-08-08 2022-10-14 苏州汉德创宏生化科技有限公司 一种4-(噁唑-2-基)苯甲酸的合成方法
WO2023139581A1 (en) * 2022-01-18 2023-07-27 Bsense Bio Therapeutics Ltd. Modulators of a potassium channel and of trpv1 channel and uses thereof

Also Published As

Publication number Publication date
IL161881A (en) 2011-01-31
US7727997B2 (en) 2010-06-01
US7176242B2 (en) 2007-02-13
AU2002359376B8 (en) 2003-05-19
AU2002359376B2 (en) 2008-01-10
WO2003040096A3 (en) 2004-05-06
RS50504A (en) 2007-04-10
EA200400648A1 (ru) 2005-04-28
HRP20040518A2 (en) 2007-08-31
US20070213316A1 (en) 2007-09-13
MXPA04004428A (es) 2004-09-10
TNSN04082A1 (en) 2006-06-01
JP2005520791A (ja) 2005-07-14
CO5640093A2 (es) 2006-05-31
AP2004003049A0 (en) 2004-06-30
CA2466284A1 (en) 2003-05-15
GEP20074171B (en) 2007-07-25
AR039555A1 (es) 2005-02-23
TW200304808A (en) 2003-10-16
IL161881A0 (en) 2005-11-20
BR0214035A (pt) 2005-04-26
KR20050044407A (ko) 2005-05-12
OA12846A (en) 2006-09-15
IS7255A (is) 2004-05-07
ECSP045100A (es) 2006-06-27
US20040171881A1 (en) 2004-09-02
EP1453789A2 (en) 2004-09-08
NZ533107A (en) 2007-04-27

Similar Documents

Publication Publication Date Title
US7727997B2 (en) N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
AU2002359376A1 (en) N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
US7294642B2 (en) 1,3-Diamino-2-hydroxypropane pro-drug derivatives
US20010044445A1 (en) Azole inhibitors of cytokine production
WO1999051580A1 (en) Pyrazole inhibitors of cytokine production
WO2006062982A2 (en) Urea inhibitors of map kinases
CZ20024194A3 (cs) Sloučeniny pro léčbu Alzheimerovy nemoci
JPH07505648A (ja) アザサイクリック化合物
IE912855A1 (en) Indole derivatives which inhibit leukotriene biosynthesis
CA2580409A1 (en) Triazole derivative or salt thereof
AU2003225730A1 (en) Substituted hydroxyethylamines
TW201323419A (zh) 經胺基烷基取代之ｎ－噻吩基苯甲醯胺衍生物
WO2020072580A1 (en) Matriptase 2 inhibitors and uses thereof
WO2019191327A1 (en) Ox2r compounds
WO1997034873A1 (fr) Derives d'aminopyridine
JP2001525398A (ja) 選択的β３アドレナリン作動性アゴニスト
CN1759095A (zh) N,n'－取代的－1,3－二氨基－2－羟基丙烷衍生物
AU2008201593A1 (en) N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
KR870001647B1 (ko) 5원 헤테로사이클 고리를 갖는 n-(비사이클 헤테로 사이클 )-4-피페리딘아민의 제조방법

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-505/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004428

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047007148

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 161881

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2466284

Country of ref document: CA

Ref document number: 2003542142

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004/03578

Country of ref document: ZA

Ref document number: 200403578

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 00627/KOLNP/2004

Country of ref document: IN

Ref document number: 627/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002359376

Country of ref document: AU

Ref document number: 533107

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1200400515

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: P20040518A

Country of ref document: HR

Ref document number: 200400648

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 5633

Country of ref document: GE

Ref document number: 8252

Country of ref document: GE

WWE Wipo information: entry into national phase

Ref document number: 2002793909

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028267869

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002793909

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500661

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2002359376

Country of ref document: AU

Date of ref document: 20021108

Kind code of ref document: B